Publikationsliste Prof. Dr. Roland Schmieder
- (2025) Response of Blood Pressure to Renal Denervation Is Not Associated With Genetic Variants. Hypertension. 2025;82(1): 118-125
- (2025) Kidney hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in diabetes: physiology and clinical implications. Clin Kidney J. 2025;18(1):
- (2025) Effects of valsartan vs amlodipine and achieved lower blood pressure on the incidence of end-stage kidney disease: The VALUE Trial. Eur J Intern Med. 2025;133(): 55-63
- (2025) Novel approaches to define responders to interventional treatment in hypertension: insights from the SPYRAL HTN-OFF and HTN-ON MED trials. Hypertens Res. 2025;48(1): 327-335
- (2025) Effect of spironolactone wash-out on albuminuria after long-term treatment in individuals with type 2 diabetes and high risk of kidney disease-An observational follow-up of the PRIORITY study. Diabetes Obes Metab. 2025;27(1): 387-393
- (2025) Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial. Nat Med. 2025;31(1): 278-285
- (2025) Effect of a single pill concept on clinical and pharmacoeconomic outcomes in cardiovascular diseases. Eur Heart J Cardiovasc Pharmacother. 2025;10(8): 686-693
- (2025) Predicting blood pressure response to renal denervation based on a new approach. J Hypertens. 2025;43(3): 413-419
- (2024) Blood pressure reduction after renal denervation in patients with or without chronic kidney disease. Clin Kidney J. 2024;17(1):
- (2024) Relation between waist circumference and the renal hemodynamic in healthy individuals. Nutr Metab Cardiovasc Dis. 2024;34(3): 755-762
- (2024) Skin sodium content as a predictor of blood pressure response to renal denervation. Hypertens Res. 2024;47(2): 361-371
- (2024) Early vascular damage in retinal microcirculation in arterial hypertension: the Czech post-MONICA study. J Hypertens. 2024;42(3): 557-563
- (2024) Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure 6 Months After Medication Escalation: The RADIANCE Clinical Trial Program. Circulation. 2024;149(10): 747-759
- (2024) Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study. Lancet. 2024;403(10421): 55-66
- (2024) Triglyceride-glucose index, low-density lipoprotein levels, and cardiovascular outcomes in chronic stable cardiovascular disease: results from the ONTARGET and TRANSCEND trials. Eur J Prev Cardiol. 2024;31(3): 311-319
- (2024) Progressive Kidney Failure by Angiotensinogen Inactivation in the Germline. Hypertension. 2024;81(9): 1857-1868
- (2024) 36-month durability of ultrasound renal denervation for hypertension resistant to combination therapy in RADIANCE-HTN TRIO. Hypertens Res. 2024;47(12): 3467-3472
- (2024) Is GFR decline induced by SGLT2 inhibitor of clinical importance? Cardiovasc Diabetol. 2024;23(1):
- (2024) PCSK-9-inhibitor therapy improves endothelial function in high-risk patients with cardiovascular disease. Clin Res Cardiol. 2024;():
- (2024) Renal adaptation in pre-obesity patients with hypertension. J Hypertens. 2024;42(11): 1958-1965
- (2024) Sodium quantification in skeletal muscle: comparison between Cartesian gradient-echo and radial ultra-short echo time 23Na MRI techniques. Eur Radiol Exp. 2024;8(1):
- (2024) The soluble guanylate cyclase activator runcaciguat significantly improves albuminuria in patients with chronic kidney disease: a randomized placebo-controlled clinical trial. Nephrol Dial Transplant. 2024;():
- (2024) Response to 'Why the lack of enthusiasm for renal denervation?'. J Hypertens. 2024;42(12): 2215-2217
- (2024) Renal Denervation Lowers Nighttime Blood Pressure in True Resistant Hypertension. Hypertension. 2024;81(12): e200-e202
- (2024) Effects of Catheter-Based Renal Denervation in Hypertension: A Systematic Review and Meta-Analysis. Circulation. 2024;150(20): 1599-1611
- (2024) Effects of catheter-based renal denervation in hypertension: a systematic review and meta-analysis. medRxiv. 2024;():
- (2024) Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial. Nat Med. 2024;30(10): 2849-2856
- (2024) Management of patients with hypertension and chronic kidney disease referred to Hypertension Excellence Centres among 27 countries. On behalf of the European Society of Hypertension Working Group on Hypertension and the Kidney. Blood Press. 2024;33(1):
- (2024) Screening and management of hypertensive patients with chronic kidney disease referred to Hypertension Excellence Centres among 27 countries. A pilot survey based on questionnaire. J Hypertens. 2024;42(9): 1544-1554
- (2024) Correction: Cost Effectiveness of Endovascular Ultrasound Renal Denervation in Patients with Resistant Hypertension. Pharmacoecon Open. 2024;8(4):
- (2024) Renal denervation for uncontrolled hypertension: a systematic review and meta-analysis examining multiple subgroups. J Hypertens. 2024;42(7): 1133-1144
- (2024) A novel, proof-of-concept radiofrequency renal denervation strategy to improve procedural efficiency: 12-month results from the SPYRAL DYSTAL pilot study. Cardiovasc Revasc Med. 2024;68(): 30-36
- (2024) Effect of Alcohol-Mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Medications: Primary Results From the TARGET BP I Randomized Clinical Trial. Circulation. 2024;149(24): 1875-1884
- (2024) Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis. Lancet Diabetes Endocrinol. 2024;12(5): 306-319
- (2024) A European Renal Association (ERA) synopsis for nephrology practice of the 2023 European Society of Hypertension (ESH) Guidelines for the Management of Arterial Hypertension. Nephrol Dial Transplant. 2024;39(6): 929-943
- (2024) Impact of Antihypertensive Medication Changes After Renal Denervation Among Different Patient Groups: SPYRAL HTN-ON MED. Hypertension. 2024;81(5): 1095-1105
- (2024) Cost Effectiveness of Endovascular Ultrasound Renal Denervation in Patients with Resistant Hypertension. Pharmacoecon Open. 2024;8(4): 525-537
- (2024) Cost-effectiveness of catheter-based radiofrequency renal denervation for the treatment of uncontrolled hypertension: an analysis for the UK based on recent clinical evidence. Eur Heart J Qual Care Clin Outcomes. 2024;10(8): 698-708
- (2024) BLOOD PRESSURE RESPONDERS TO RENAL DENERVATION BASED ON A NEW DEFINITION J Hypertens. 2024;42 Suppl 1():
- (2024) WHY HAPPENS A PROGRESSIVE DECREASE OF BLOOD PRESSURE AFTER RENAL DENERVATION J Hypertens. 2024;42 Suppl 1():
- (2024) INCREASE IN ARTERIAL STIFFNESS IN LIVING KIDNEY DONORS AFTER RENAL DONATION J Hypertens. 2024;42 Suppl 1():
- (2024) Ultrasound-Based Renal Denervation Reduces Blood Pressure in Patients With Chronic Kidney Disease: Results of a Multicenter Prospective Randomized Sham-Controlled Blinded Investigator Initiated Trial J Am Coll Cardiol. 2024;84 Suppl S(18): B159-B159
- (2024) EFFECT OF RENAL DENERVATION ON BLOOD PRESSURE IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND UNCONTROLLED HYPERTENSION: RESULTS OF A PROSPECTIVE RANDOMIZED SHAM-CONTROLLED STUDY J Hypertens. 2024;42 Suppl 1():
- (2024) Benefits of Semaglutide on Chronic Kidney Disease Outcomes by Cardiovascular Status or Risk in the FLOW trial Circulation. 2024;150(25): E746-E746
- (2024) Renal Artery Imaging Through Long-Term Follow-up Following Radiofrequency Renal Denervation: Results From the SPYRAL Clinical Trial Program J Am Coll Cardiol. 2024;84 Suppl S(18): B157-B158
- (2024) SIGNIFICANT NIGHTTIME BLOOD PRESSURE REDUCTIONS FOLLOWING RENAL DENERVATION IN PATIENTS WITH UNCONTROLLED HYPERTENSION: POOLED ANALYSIS FROM THE SPYRAL HTN TRIALS J Hypertens. 2024;42 Suppl 3(SUPPL 3):
- (2024) Chronic Kidney Disease in Type 2 Diabetes - the Silent Threat of a Multisystem Disorder Aktuelle Kardiol. 2024;13(04): 296-301
- (2024) SIGNIFICANT NIGHTTIME BLOOD PRESSURE REDUCTIONS AFTER RADIOFREQUENCY RENAL DENERVATION IN PATIENTS WITH UNCONTROLLED HYPERTENSION: POOLED ANALYSIS OF THE SPYRAL HTN TRIALS J Hypertens. 2024;42 Suppl 1():
- (2024) RENAL DENERVATION RESULTS IN SUBSTANTIAL NOCTURNAL BP REDUCTION IN PATIENTS WITH A REVERSED DIPPING PATTERN J Hypertens. 2024;42 Suppl 1():
- (2024) ACHIEVED SYSTOLIC BLOOD PRESSURE BELOW 130 MMHG PRESERVES KIDNEY FUNCTION IN HIGH-RISK HYPERTENSIVE PATIENTS WITHOUT CARDIAC HYPERTROPHY BUT WITH PROTEINURIA J Hypertens. 2024;42 Suppl 1():
- (2024) ACHIEVED SYSTOLIC BLOOD PRESSURE BELOW 130 MMHG PRESERVES KIDNEY FUNCTION IN DIABETIC AND NON-DIABETIC HYPERTENSIVE PATIENTS WITHOUT CARDIAC HYPERTROPHY J Hypertens. 2024;42 Suppl 1():
- (2024) THREE-YEAR NIGHTTIME BLOOD PRESSURE REDUCTIONS AFTER RADIOFREQUENCY RENAL DENERVATION IN PATIENTS WITH UNCONTROLLED HYPERTENSION AND CHRONIC KIDNEY DISEASE J Hypertens. 2024;42 Suppl 1():
- (2024) HIGHER BASELINE SYSTOLIC BLOOD PRESSURE IS ASSOCIATED WITH GREATER BLOOD PRESSURE REDUCTIONS FOLLOWING RADIOFREQUENCY RENAL DENERVATION IN A POOLED COHORT OF OVER 3900 PATIENTS J Hypertens. 2024;42 Suppl 1():
- (2024) LONG-TERM OUTCOMES FOLLOWING RADIOFREQUENCY RENAL DENERVATION: META-ANALYSIS OF 18 REPORTS INCLUDING PATIENT LEVEL DATA FROM THE GLOBAL SYMPLICITY REGISTRY DEFINE J Am Coll Cardiol. 2024;83 Suppl S(13): 1032-1032
- (2024) THREE-YEAR NIGHTTIME BLOOD PRESSURE AFTER RADIOFREQUENCY RENAL DENERVATION IN PATIENTS WITH UNCONTROLLED HYPERTENSION AND CHRONIC KIDNEY DISEASE Am J Kidney Dis. 2024;83 Suppl 2(4): S132-S132
- (2024) META -ANALYSIS OF LONG-TERM OUTCOMES FOLLOWING RADIO FREQUENCY RENAL DEN E RVATION Am J Kidney Dis. 2024;83 Suppl 2(4): S131-S131
- (2024) Systematic Review of Renal Denervation for Uncontrolled Hypertension: Meta-Analysis Results for Office, 24-Hour, and Daytime Ambulatory Blood Pressure JACC Cardiovasc Interv. 2024;17 Suppl S(4): S63-S64
- (2024) Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024;391(2): 109-121
- (2024) Renal Denervation Is Effective in Reducing Blood Pressure in Patients with CKD: Results of a Multicenter, Prospective, Randomized, Sham-Controlled, Blinded, Investigator-Initiated Trial J Am Soc Nephrol. 2024;35 Suppl S(10):
- (2024) Increased Blood Pressure in Mice with Impaired Function of Afferent Renal Nerves Due to Lack of Sodium Nav1.8 Channels J Am Soc Nephrol. 2024;35 Suppl S(10):
- (2024) Increase in Arterial Stiffness in Living Kidney Donors after Kidney Donation J Am Soc Nephrol. 2024;35 Suppl S(10):
- (2023) SKIN SODIUM CONTENT AS A PREDICTOR OF BLOOD PRESSURE RESPONSE TO RENAL DENERVATION J Hypertens. 2023;41 Suppl 3(): E250-E251
- (2023) IS GFR DECLINE INDUCED BY SGLT-2 INHIBITOR OF CLINICAL IMPORTANCE? Nephrol Dial Transplant. 2023;38 Suppl 1(): I87-I88
- (2023) BLOOD PRESSURE REDUCTION AFTER RENAL DENERVATION IN PATIENTS WITH OR WITHOUT CHRONIC KIDNEY DISEASE: THE ERLANGER EXPERIENCE J Hypertens. 2023;41 Suppl 3(): E256-E256
- (2023) PCSK-9-INHIBITOR THERAPY IMPROVES ENDOTHELIAL FUNCTION IN HIGH-RISK PATIENTS WITH CARDIOVASCULAR DISEASE J Hypertens. 2023;41 Suppl 1(): E293-E293
- (2023) BLOOD PRESSURE REDUCTION AFTER RENAL DENERVATION IN PATIENTS WITH OR WITHOUT CHRONIC KIDNEY DISEASE: THE ERLANGER EXPERIENCE J Hypertens. 2023;41 Suppl 1(): E484-E484
- (2023) A Novel Method For The Analysis Of Renal Sympathetic Nerve Activity From Multi-fiber Nerve Recordings Hypertension. 2023;80 Suppl 1():
- (2023) The Positive Effect Of Renal Denervation Persists Even Through Regrowth Of Afferent Axons Improving Renal Afferent Nerve Activity During High Sodium Intake In Rats Hypertension. 2023;80 Suppl 1():
- (2023) Significance Of The Nav 1.8. Voltage-gated, Tetrodotoxin-resistant Sodium Channel For The Renal Sensory Innervation In Mice And Rats Hypertension. 2023;80 Suppl 1():
- (2023) EMPAGLIFLOZIN IMPROVES IMPAIRED SENSITIVITY OF AFFERENT NEURONS WITH RENAL AXONS J Hypertens. 2023;41 Suppl 3(): E75-E75
- (2023) HIGH SODIUM INTAKE - EFFECTS ON AFFERENT RENAL NERVE ACTIVITY J Hypertens. 2023;41 Suppl 3(): E75-E75
- (2023) Is GFR decline induced by SGLT-2 inhibitor of clinical importance? Diabetologia. 2023;66 Suppl 1(SUPPL 1): S352-S352
- (2023) EFFECT OF PCSK9 INHIBITION WITH EVOLOCUMAB ON THE CONCENTRATION AND COMPOSITION OF LDL SUBFRACTIONS IN HIGH-RISK PATIENTS WITH CARDIOVASCULAR DISEASE Atherosclerosis. 2023;379 Suppl 1(): S71-S71
- (2023) RENAL IMAGING IN HYPERTENSION J Hypertens. 2023;41 Suppl 1(): E18-E18
- (2023) RESPONSE OF BLOOD PRESSURE TO RENAL DENERVATION IS NOT ASSOCIATED WITH GENETIC VARIANTS J Hypertens. 2023;41 Suppl 3(): E52-E53
- (2023) Cost-Effectiveness of Catheter-Based Radiofrequency Renal Denervation for the Treatment of Uncontrolled Hypertension: An Analysis for the UK Based on Recent Clinical Evidence JACC Cardiovasc Interv. 2023;16 Suppl S(4): S82-S82
- (2023) LONG-TERM REDUCTION IN MORNING AND NIGHTTIME BLOOD PRESSURE AFTER RENAL DENERVATION: 36-MONTH RESULTS FROM SPYRAL HTN-ON MED PILOT TRIAL J Hypertens. 2023;41 Suppl 1(): E80-E80
- (2023) Endovascular Ultrasound Renal Denervation to Treat Uncontrolled Hypertension: 6-Month Results Following Blinded Medication Titration in the Randomized, Sham-Controlled RADIANCE II Pivotal Trial J Am Coll Cardiol. 2023;82 Suppl S(17): B159-B159
- (2023) Comments on the consensus paper on renal denervation of the working group on hypertension of the European Society of Cardiology (ESC) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) Kardiologie. 2023;17(4): 242-251
- (2023) Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. Nephrol Dial Transplant. 2023;38(1): 10-25
- (2023) Renal denervation in patients with chronic kidney disease: current evidence and future perspectives. Nephrol Dial Transplant. 2023;38(5): 1089-1096
- (2023) The SGLT2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure: results from a placebo-controlled randomised trial. Clin Res Cardiol. 2023;112(1): 134-144
- (2023) Is vascular remodelling in patients with chronic heart failure exaggerated? ESC Heart Fail. 2023;10(1): 245-254
- (2023) Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes. J Hypertens. 2023;41(2): 295-302
- (2023) Long-term reduction in morning and nighttime blood pressure after renal denervation: 36-month results from SPYRAL HTN-ON MED trial. Hypertens Res. 2023;46(1): 280-288
- (2023) Clinical event reductions in high-risk patients after renal denervation projected from the global SYMPLICITY registry. Eur Heart J Qual Care Clin Outcomes. 2023;9(6): 575-582
- (2023) Sex Differences in Blood Pressure and Potential Implications for Cardiovascular Risk Management. Hypertension. 2023;80(2): 316-324
- (2023) Angiotensin pathways under therapy with empagliflozin in patients with chronic heart failure. ESC Heart Fail. 2023;10(3): 1635-1642
- (2023) Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2023;44(15): 1313-1330
- (2023) Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). EuroIntervention. 2023;18(15): 1227-1243
- (2023) Impact of type 1 diabetes and its duration on wall-to-lumen ratio and blood flow in retinal arterioles. Microvasc Res. 2023;147():
- (2023) Safety and Efficacy of Renal Denervation in Patients Taking Antihypertensive Medications. J Am Coll Cardiol. 2023;82(19): 1809-1823
- (2023) Determinants of arterial stiffness in patients with type 2 diabetes mellitus: a cross sectional analysis. Sci Rep. 2023;13(1):
- (2023) Afferent neurons of the kidney with impaired firing pattern in inflammation - role of sodium currents? Pflugers Arch. 2023;475(11): 1329-1342
- (2023) Myocardial infarction with a preserved ejection fraction-the impaired function of the cardio-renal baroreflex. Front Physiol. 2023;14():
- (2023) Patient-Level Pooled Analysis of Ultrasound Renal Denervation in the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO Trials. JAMA Cardiol. 2023;8(5): 464-473
- (2023) Endovascular Ultrasound Renal Denervation to Treat Hypertension: The RADIANCE II Randomized Clinical Trial. JAMA. 2023;329(8): 651-661
- (2023) Cardiovascular and health cost impacts of cuff blood pressure underestimation and overestimation of invasive aortic systolic blood pressure. J Hypertens. 2023;41(10): 1585-1594
- (2023) Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis. Ann Intern Med. 2023;176(12): 1606-1616
- (2023) Long-term efficacy and safety of renal denervation: an update from registries and randomised trials. Blood Press. 2023;32(1):
- (2023) Renal Denervation: A Practical Guide for Health Professionals Managing Hypertension. Interv Cardiol. 2023;18():
- (2023) Alcohol-mediated renal denervation in patients with hypertension in the absence of antihypertensive medications. EuroIntervention. 2023;19(7): 602-611
- (2023) 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12): 1874-2071
- (2023) Outcomes Following Radiofrequency Renal Denervation According to Antihypertensive Medications: Subgroup Analysis of the Global SYMPLICITY Registry DEFINE. Hypertension. 2023;80(8): 1759-1770
- (2023) Atherosclerotic renovascular disease: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA) and the Working Group Hypertension and the Kidney of the European Society of Hypertension (ESH). Nephrol Dial Transplant. 2023;38(12): 2835-2850
- (2023) Improved Persistence to Medication, Decreased Cardiovascular Events and Reduced All-Cause Mortality in Hypertensive Patients With Use of Single-Pill Combinations: Results From the START-Study. Hypertension. 2023;80(5): 1127-1135
- (2023) Erratum. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. Diabetes Care 2022;45:888-897. Diabetes Care. 2023;46(9):
- (2023) RELATION BETWEEN WAIST CIRCUMFERENCE AND THE RENAL HEMODYNAMIC IN PATIENTS WITH UNCOMPLICATED HYPERTENSION GRADE 1-2 J Hypertens. 2023;41 Suppl 3(): E264-E264
- (2023) RENAL DENERVATION REDUCES RETINAL ARTERIAL REMODELING IN PATIENTS WITH TREATMENT RESISTANT HYPERTENSION AND TYPE 2 DIABETES MELLITUS J Hypertens. 2023;41 Suppl 3(): E296-E297
- (2022) Renal denervation in patients with versus without chronic kidney disease: results from the Global SYMPLICITY Registry with follow-up data of 3 years. Nephrol Dial Transplant. 2022;37(2): 304-310
- (2022) Diagnosis and treatment of arterial hypertension 2021. Kidney Int. 2022;101(1): 36-46
- (2022) The influence of aircraft noise exposure on the systemic and renal haemodynamics. Eur J Prev Cardiol. 2022;29(1): 116-124
- (2022) [Renal denervation : Really an alternative to reducing blood pressure?] Internist (Berl). 2022;63(3): 330-340
- (2022) Plasma renin and aldosterone concentrations related to endovascular ultrasound renal denervation in the RADIANCE-HTN SOLO trial. J Hypertens. 2022;40(2): 221-228
- (2022) Twenty-Four-Hour Pulsatile Hemodynamics Predict Brachial Blood Pressure Response to Renal Denervation in the SPYRAL HTN-OFF MED Trial. Hypertension. 2022;79(7): 1506-1514
- (2022) Effects of cardiovascular single pill combinations compared with identical multi-pill therapies on healthcare cost and utilization in Germany. J Comp Eff Res. 2022;11(6): 411-422
- (2022) High cholesterol absorption is associated with increased cardiovascular risk in haemodialysis patients: insights from the AURORA study. Eur J Prev Cardiol. 2022;29(13): 1731-1739
- (2022) Effects of Single Pill Combinations Compared to Identical Multi Pill Therapy on Outcomes in Hypertension, Dyslipidemia and Secondary Cardiovascular Prevention: The START-Study. Integr Blood Press Control. 2022;15(): 11-21
- (2022) Clinical Trial Design Principles and Outcomes Definitions for Device-Based Therapies for Hypertension: A Consensus Document From the Hypertension Academic Research Consortium. Circulation. 2022;145(11): 847-863
- (2022) Association between exercise frequency with renal and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk. Cardiovasc Diabetol. 2022;21(1):
- (2022) Letter regarding "diagnosis and treatment of arterial hypertension 2021" reply Kidney Int. 2022;101(4): 830-832
- (2022) 10-YEAR CLINICAL EVENTS AVOIDED IN DIABETIC AND CHRONIC KIDNEY DISEASE HYPERTENSION PATIENTS TREATED WITH RADIOFREQUENCY RENAL DENERVATION: PROJECTIONS BASED ON 3-YEAR DATA FROM THE GLOBAL SYMPLICITY REGISTRY Nephrol Dial Transplant. 2022;37 Suppl 3(): I54-I54
- (2022) Reduction of Clinical Events in High-Risk Hypertension Patients Treated With Renal Denervation: A Modeled Estimate From 36-Month Global SYMPLICTY Registry Data J Am Coll Cardiol. 2022;79 Suppl S(15): S30-S31
- (2022) Physician Preferences for Recommending Renal Denervation to Hypertensive Patients Is Influenced by Patients' Antihypertensive Medication Nonadherence Due to Medication Side Effects J Am Coll Cardiol. 2022;79 Suppl S(15): S30-S30
- (2022) Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial. Lancet. 2022;399(10333): 1401-1410
- (2022) Change of renal function after short-term use of cardioprotective agents in patients with type 2 diabetes is not accurately assessed by the change of estimated glomerular filtration rate: an observational study. Diabetol Metab Syndr. 2022;14(1):
- (2022) Cardiovascular Risk Reduction After Renal Denervation According to Time in Therapeutic Systolic Blood Pressure Range. J Am Coll Cardiol. 2022;80(20): 1871-1880
- (2022) Effects of Renal Denervation vs Sham in Resistant Hypertension After Medication Escalation: Prespecified Analysis at 6 Months of the RADIANCE-HTN TRIO Randomized Clinical Trial. JAMA Cardiol. 2022;7(12): 1244-1252
- (2022) Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes. Hypertension. 2022;79(12): 2685-2695
- (2022) New strategies to improve clinical outcomes for diabetic kidney disease. BMC Med. 2022;20(1):
- (2022) Hypertension urgencies in the SPYRAL HTN-OFF MED Pivotal trial. Clin Res Cardiol. 2022;111(11): 1269-1275
- (2022) Empagliflozin Improves Impaired Sensitivity Of Afferent Neurons With Renal Axons Hypertension. 2022;79 Suppl 1():
- (2022) High Sodium Intake Effects On Afferent Renal Nerve Activity Hypertension. 2022;79 Suppl 1():
- (2022) Evolocumab Alters Vascular Function in Patients With Cardiovascular Disease Circulation. 2022;146 Suppl 1():
- (2022) ANGIOTENSIN PROFILES IN PATIENTS WITH HYPERTENSION AND TYPE 2 DIABETES WITH COMBINATION THERAPY OF EMPAGLIFLOZIN AND LINAGLIPTIN VERSUS METFORMIN AND INSULIN GLARGINE J Hypertens. 2022;40 Suppl 1(SUPPL 1): E283-E284
- (2022) IS BASAL NITRIC OXIDE ACTIVITY OF THE RENAL VASCULATURE ALTERED? ANALYSIS OF A RANDOMIZED CONTROLLED TRIAL COMPARING TWO COMBINATION THERAPIES J Hypertens. 2022;40 Suppl 1(SUPPL): E59-E59
- (2022) SEMI-AUTOMATIC MEASUREMENT OF INTIMA-MEDIA THICKNESS OF BRACHIAL ARTERY IN PATIENTS WITH CONGESTIVE HEART FAILURE J Hypertens. 2022;40 Suppl 1(SUPPL): E239-E239
- (2022) SEMI-AUTOMATIC MEASUREMENT OF INTIMA-MEDIA THICKNESS OF BRACHIAL ARTERY IN PATIENTS WITH CONGESTIVE HEART FAILURE J Hypertens. 2022;40 Suppl 1(SUPPL): E239-E239
- (2022) IS BASAL NITRIC OXIDE ACTIVITY OF THE RENAL VASCULATURE ALTERED? ANALYSIS OF A RANDOMIZED CONTROLLED TRIAL COMPARING TWO COMBINATION THERAPIES J Hypertens. 2022;40 Suppl 1(SUPPL): E59-E59
- (2022) DETAILED ANALYSIS OF VASCULAR STIFFNESS IN PATIENTS WITH CHRONIC HEART FAILURE J Hypertens. 2022;40 Suppl 1(SUPPL 1): E129-E129
- (2022) DETAILED ANALYSIS OF VASCULAR STIFFNESS IN PATIENTS WITH CHRONIC HEART FAILURE J Hypertens. 2022;40 Suppl 1(SUPPL): E129-E129
- (2022) Influence of Gender on Blood Pressure Reduction After Renal Denervation in GSR DEFINE J Am Coll Cardiol. 2022;80 Suppl S(12): B230-B230
- (2022) LONG-TERM RESULTS FROM THE SPYRAL HTN-ON MED TRIAL: RENAL DENERVATION INCREASES TIME IN BLOOD PRESSURE TARGET RANGE OVER 36 MONTHS J Hypertens. 2022;40 Suppl 1(SUPPL): E10-E11
- (2022) LONG-TERM RESULTS FROM THE SPYRAL HTN-ON MED TRIAL: RENAL DENERVATION INCREASES TIME IN BLOOD PRESSURE TARGET RANGE OVER 36 MONTHS J Hypertens. 2022;40 Suppl 1(SUPPL): E10-E11
- (2022) Twenty-Four Month Results in Patients With Resistant Hypertension After Endovascular Ultrasound Renal Denervation in the RADIANCE-HTN TRIO Trial J Am Coll Cardiol. 2022;80 Suppl S(12): B85-B86
- (2022) CLINICAL EVENT REDUCTIONS IN HIGH-RISK HYPERTENSION PATIENTS TREATED WITH RENAL DENERVATION: 10-YEAR PROJECTIONS BASED ON 3-YEAR FOLLOW-UP FROM THE GLOBAL SYMPLICITY REGISTRY J Hypertens. 2022;40 Suppl 1(SUPPL): E55-E56
- (2022) CLINICAL EVENT REDUCTIONS IN HIGH-RISK HYPERTENSION PATIENTS TREATED WITH RENAL DENERVATION: 10-YEAR PROJECTIONS BASED ON 3-YEAR FOLLOW-UP FROM THE GLOBAL SYMPLICITY REGISTRY J Hypertens. 2022;40 Suppl 1(SUPPL): E55-E56
- (2022) BLOOD PRESSURE REDUCTION AFTER CATHETER-BASED RENAL DENERVATION IN PATIENTS WITH CARDIOVASCULAR DISEASE IN THE GLOBAL SYMPLICITY REGISTRY J Hypertens. 2022;40 Suppl 1(SUPPL): E290-E290
- (2022) BLOOD PRESSURE REDUCTION AFTER CATHETER-BASED RENAL DENERVATION IN PATIENTS WITH CARDIOVASCULAR DISEASE IN THE GLOBAL SYMPLICITY REGISTRY J Hypertens. 2022;40 Suppl 1(SUPPL): E290-E290
- (2022) Effect of Radiofrequency Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 6-Month Primary Results From the SPYRAL HTN-ON Med Expansion Randomized Trial Circulation. 2022;146(25): E584-E584
- (2022) NT-proBNP and stem cell factor plasma concentrations are independently associated with cardiovascular outcomes in end-stage renal disease hemodialysis patients. Eur Heart J Open. 2022;2(6):
- (2022) Renal denervation: where do we stand and what is the relevance to the nephrologist? Nephrol Dial Transplant. 2022;37(4): 638-644
- (2022) Serum markers of fibrosis, cardiovascular and all-cause mortality in hemodialysis patients: the AURORA trial. Clin Res Cardiol. 2022;111(6): 614-626
- (2022) Predictors of blood pressure response to ultrasound renal denervation in the RADIANCE-HTN SOLO study. J Hum Hypertens. 2022;36(7): 629-639
- (2022) Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers. Cardiovasc Diabetol. 2022;21(1):
- (2022) Editorial comment: Renal denervation. Hypertens Res. 2022;45(2): 241-243
- (2021) Novel approaches to management of hypertension. Curr Opin Nephrol Hypertens. 2021;30(1): 54-62
- (2021) How to measure retinal microperfusion in patients with arterial hypertension. Blood Press. 2021;30(1): 4-19
- (2021) 3D-Visualization of Neurovascular Compression at the Ventrolateral Medulla in Patients with Arterial Hypertension. Clin Neuroradiol. 2021;31(2): 335-345
- (2021) Reference values of retinal microcirculation parameters derived from a population random sample. Microvasc Res. 2021;134():
- (2021) Effect of renal denervation in attenuating the stress of morning surge in blood pressure: post-hoc analysis from the SPYRAL HTN-ON MED trial. Clin Res Cardiol. 2021;110(5): 725-731
- (2021) Alcohol-Mediated Renal Sympathetic Neurolysis for the Treatment of Hypertension: The Peregrine™ Infusion Catheter. Cardiovasc Revasc Med. 2021;24(): 77-86
- (2021) Identifying Isolated Systolic Hypertension From Upper-Arm Cuff Blood Pressure Compared With Invasive Measurements. Hypertension. 2021;77(2): 632-639
- (2021) Renal and intraglomerular haemodynamics in chronic heart failure with preserved and reduced ejection fraction. ESC Heart Fail. 2021;8(2): 1562-1570
- (2021) Improved blood pressure control via a novel chronic disease management model of care in sub-Saharan Africa: Real-world program implementation results. J Clin Hypertens (Greenwich). 2021;23(4): 785-792
- (2021) Differences in patient and physician perspectives on pharmaceutical therapy and renal denervation for the management of hypertension. J Hypertens. 2021;39(1): 162-168
- (2021) Renal outcomes and blood pressure patterns in diabetic and nondiabetic individuals at high cardiovascular risk. J Hypertens. 2021;39(4): 766-774
- (2021) Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine. Cardiovasc Diabetol. 2021;20(1):
- (2021) Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure. ESC Heart Fail. 2021;8(6): 5327-5337
- (2021) Effect of Heart Rate on the Outcome of Renal Denervation in Patients With Uncontrolled Hypertension. J Am Coll Cardiol. 2021;78(10): 1028-1038
- (2021) AT II Receptor Blockade and Renal Denervation: Different Interventions with Comparable Renal Effects? Kidney Blood Press Res. 2021;46(3): 331-341
- (2021) Responsiveness of afferent renal nerve units in renovascular hypertension in rats. Pflugers Arch. 2021;473(10): 1617-1629
- (2021) Update on Treatment of Hypertension After Renal Transplantation. Curr Hypertens Rep. 2021;23(5):
- (2021) Association of Noise Annoyance with Measured Renal Hemodynamic Changes. Kidney Blood Press Res. 2021;46(3): 323-330
- (2021) Response to: Cavagna et al The importance of considering cultural and environmental elements in an interventional model of care to fight hypertension in Africa. J Clin Hypertens (Greenwich). 2021;23(6): 1271-1272
- (2021) Cardiovascular outcomes in patients at high cardiovascular risk with previous myocardial infarction or stroke. J Hypertens. 2021;39(8): 1602-1610
- (2021) Sex-specific differences and long-term outcome of patients with coronary artery disease and chronic kidney disease: the Coronary Artery Disease and Renal Failure (CAD-REF) Registry. Clin Res Cardiol. 2021;110(10): 1625-1636
- (2021) Changes in Plasma Renin Activity After Renal Artery Sympathetic Denervation. J Am Coll Cardiol. 2021;77(23): 2909-2919
- (2021) Catheter-based alcohol-mediated renal denervation for the treatment of uncontrolled hypertension: design of two sham-controlled, randomized, blinded trials in the absence (TARGET BP OFF-MED) and presence (TARGET BP I) of antihypertensive medications. Am Heart J. 2021;239(): 90-99
- (2021) Long-Term Results up to 12 Months After Catheter-Based Alcohol-Mediated Renal Denervation for Treatment of Resistant Hypertension. Circ Cardiovasc Interv. 2021;14(9):
- (2021) Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. Lancet. 2021;397(10293): 2476-2486
- (2021) European Society of Hypertension position paper on renal denervation 2021. J Hypertens. 2021;39(9): 1733-1741
- (2021) Tissue sodium content correlates with hypertrophic vascular remodeling in type 2 diabetes. J Diabetes Complications. 2021;35(12):
- (2021) Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure. Cardiovasc Diabetol. 2021;20(1):
- (2021) Reduced tissue sodium content is related to improvement of vascular function in patients with chronic heart failure treated with the SGLT2 inhibitor empagliflozin Eur Heart J. 2021;42 Suppl 1(): 795-795
- (2021) Effect of SGLT2 inhibition on ketone bodies in patients with stable chronic heart failure Diabetologia. 2021;64 Suppl 1(SUPPL 1): 107-107
- (2021) Angiotensin profiles in patients with type 2 diabetes and combination therapy of empagliflozin and linagliptin versus metformin and insulin glargine Diabetologia. 2021;64 Suppl 1(SUPPL 1): 256-256
- (2021) Changes in blood pressure after crossover to ultrasound renal denervation in patients initially treated with sham in the RADIANCE-HTN SOLO trial. EuroIntervention. 2021;17(12): e1024-e1032
- (2021) Predictors of blood pressure response after renal denervation beyond pretreatment blood pressure Eur Heart J. 2021;42 Suppl 1(): 2379-2379
- (2021) Reasons for antihypertensive medication nonadherence influence physician preferences for hypertension management Eur Heart J. 2021;42 Suppl 1(): 2375-2375
- (2021) Application of win ratio methodology in the Global SYMPLICITY Registry for patients with atrial fibrillation or obstructive sleep apnea Eur Heart J. 2021;42 Suppl 1(): 2376-2376
- (2021) Detection of Changes in Renal Blood Flow Using Arterial Spin Labeling MRI. Am J Nephrol. 2021;52(1): 69-75
- (2021) Hypertrophic remodelling of retinal arterioles in patients with congestive heart failure. ESC Heart Fail. 2021;8(3): 1892-1900
- (2021) Dependency of flow-mediated vasodilatation from basal nitric oxide activity. Clin Physiol Funct Imaging. 2021;41(4): 310-316
- (2021) RELATION BETWEEN NOISE ANNOYANCE, STRESS HORMONES AND THE RENAL HEMODYNAMIC J Hypertens. 2021;39 Suppl 1(): E178-E178
- (2021) ANNOYANCE DUE TO NOISE TRIGGERS VASCULAR CHANGES IN THE RENAL HEMODYNAMIC J Hypertens. 2021;39 Suppl 1(): E169-E169
- (2021) LOW DOSE-EPLERENONE TREATMENT DECREASES AORTIC STIFFNESS IN PATIENTS WITH METABOLIC SYNDROME J Hypertens. 2021;39 Suppl 1(): E338-E338
- (2021) DETECTION OF CHANGES IN RENAL BLOOD FLOW USING ARTERIAL SPIN LABELING MRI J Hypertens. 2021;39 Suppl 1(): E307-E307
- (2021) CAN WE IDENTIFY GLOMERULAR HYPERFILTRATION IN PATIENTS WITH TYPE 2 DIABETES BY CLINICAL PARAMETERS? J Hypertens. 2021;39 Suppl 1(): E211-E211
- (2021) Neurogenic substance P-influences on action potential production in afferent neurons of the kidney? Pflugers Arch. 2021;473(4): 633-646
- (2021) AFFERENT PEPTIDERGIC NERVE FIBERS - IMPORTANCE FOR THE SALT METABOLISM BEYOND THE KIDNEYS? J Hypertens. 2021;39 Suppl 1(): E15-E15
- (2021) DIFFERENT FORMS OF AFFERENT NERVE INPUT IN CARDIAC AND RENAL DISEASE IN RATS? J Hypertens. 2021;39 Suppl 1(): E249-E250
- (2021) AFFERENT RENAL NERVE PATHWAYS IN RATS - RESPONSIVENESS TO HIGH SALT INTAKE J Hypertens. 2021;39 Suppl 1(): E250-E250
- (2021) EFFECTS OF FINERENONE ON CARDIORENAL OUTCOMES IN BLOOD PRESSURE SUBGROUPS IN PATIENTS WITH CKD AND T2D Nephrol Dial Transplant. 2021;36 Suppl 1():
- (2021) THE SINGLE PILL CONCEPT LEADS TO IMPROVED PERSISTENCE OF MEDICATION, CLINICAL OUTCOMES AND REDUCED ALL-CAUSE MORTALITY IN HYPERTENSIVE PATIENTS - RESULTS FROM THE START PROJECT J Hypertens. 2021;39 Suppl 1(): E378-E378
- (2021) THE SGLT2 INHIBITOR EMPAGLIFLOZIN REDUCES TISSUE SODIUM CONTENT IN PATIENTS WITH CHRONIC HEART FAILURE J Am Coll Cardiol. 2021;77 Suppl 1(18): 585-585
- (2021) EFFECTS OF THE SGLT2 INHIBITOR EMPAGLIFLOZIN ON VASCULAR FUNCTION IN PATIENTS WITH CHRONIC HEART FAILURE J Am Coll Cardiol. 2021;77 Suppl 1(18): 1806-1806
- (2020) High Sodium Diet - Role in Renal Sympathodepression FASEB J. 2020;34 Suppl 1():
- (2020) Single pill regimen improves persistence and leads lo better clinical outcome compared to identical multi pill combination. Results of START, a German claims data analysis Eur Heart J. 2020;41 Suppl 2(): 2770-2770
- (2020) Persistence and cardiovascular outcomes with ramipril, atorvastatin, ASA as a single pill compared to the multi pill combination. A subanalysis of the START study, a claims data analysis Eur Heart J. 2020;41 Suppl 2(): 2964-2964
- (2020) Variability of MRI Aortic Stiffness Measurements in a Multicenter Clinical Trial Setting: Intraobserver, Interobserver, and Intracenter Variability of Pulse Wave Velocity and Aortic Strain Measurement. Radiol Cardiothorac Imaging. 2020;2(2):
- (2020) Arteriovenous fistula thrombosis is associated with increased all-cause and cardiovascular mortality in haemodialysis patients from the AURORA trial. Clin Kidney J. 2020;13(1): 116-122
- (2020) Combination of empagliflozin and linagliptin improves blood pressure and vascular function in type 2 diabetes. Eur Heart J Cardiovasc Pharmacother. 2020;6(6): 364-371
- (2020) Neurogenic tachykinin mechanisms in experimental nephritis of rats. Pflugers Arch. 2020;472(12): 1705-1717
- (2020) Visit-to-visit blood pressure variability and renal outcomes: results from ONTARGET and TRANSCEND trials. J Hypertens. 2020;38(10): 2050-2058
- (2020) Tissue sodium content in hypertension and related organ damage. J Hypertens. 2020;38(12): 2363-2368
- (2020) Impact of Renal Denervation on Plasma Renin Activity and Relationship of Baseline Plasma Renin Activity to Blood Pressure Lowering Response to Renal Denervation in the SPYRAL HTN-OFF MED Pivotal trial J Am Coll Cardiol. 2020;76 Suppl S(17): B179-B179
- (2020) Patients With Resistant Hypertension in the Global SYMPLICITY Registry: Antihypertensive Medication Burden and Changes in Blood Pressure out to 3 Years J Am Coll Cardiol. 2020;76 Suppl S(17): B179-B180
- (2020) Confounding Factors in Renal Denervation Trials: Revisiting Old and Identifying New Challenges in Trial Design of Device Therapies for Hypertension. Hypertension. 2020;76(5): 1410-1417
- (2020) Afferent renal innervation in anti-Thy1.1 nephritis in rats. Am J Physiol Renal Physiol. 2020;319(5): F822-F832
- (2020) Blood pressure profile, sympathetic nervous system activity, and subclinical target organ damage in patients with polycythemia vera. Pol Arch Intern Med. 2020;130(7-8): 607-614
- (2020) Retinal arterial remodeling in patients with pheochromocytoma or paraganglioma and its reversibility following surgical treatment. J Hypertens. 2020;38(8): 1551-1558
- (2020) Relationship Between Ubiquitin-Specific Peptidase 18 and Hypertension in Polish Adult Male Subjects: A Cross-Sectional Pilot Study. Med Sci Monit. 2020;26():
- (2020) Aortic stiffness is not only associated with structural but also functional parameters of retinal microcirculation. Microvasc Res. 2020;129():
- (2020) Renal Denervation in High-Risk Patients With Hypertension. J Am Coll Cardiol. 2020;75(23): 2879-2888
- (2020) Facing the Challenge of Lowering Blood Pressure and Cholesterol in the Same Patient: Report of a Symposium at the European Society of Hypertension. Cardiol Ther. 2020;9(1): 19-34
- (2020) Medication adherence in hypertension. J Hypertens. 2020;38(4): 579-587
- (2020) Influence of Age on Upper Arm Cuff Blood Pressure Measurement. Hypertension. 2020;75(3): 844-850
- (2020) Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial. Eur Heart J. 2020;41(30): 2848-2859
- (2020) Retinal neurodegeneration in patients with end-stage renal disease assessed by spectral-domain optical coherence tomography. Sci Rep. 2020;10(1):
- (2020) Changes in Stroke Volume After Renal Denervation: Insight From Cardiac Magnetic Resonance Imaging. Hypertension. 2020;75(3): 707-713
- (2020) Proceedings from the 3rd European Clinical Consensus Conference for clinical trials in device-based hypertension therapies. Eur Heart J. 2020;41(16): 1588-1599
- (2020) Improved cardiovascular risk prediction in patients with end-stage renal disease on hemodialysis using machine learning modeling and circulating microribonucleic acids. Theranostics. 2020;10(19): 8665-8676
- (2020) Copeptin Levels in Patients With Treatment-Resistant Hypertension Before and 6 Months After Renal Denervation. Am J Hypertens. 2020;33(2): 182-189
- (2020) 12-Month Results From the Unblinded Phase of the RADIANCE-HTN SOLO Trial of Ultrasound Renal Denervation. JACC Cardiovasc Interv. 2020;13(24): 2922-2933
- (2020) Correction to: Rationale and design of two randomized sham‑controlled of catheter‑based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN‑OFF MED Pivotal) and presence (SPYRAL HTN‑ON MED Expansion) of antihypertensive medications: a novel approach using Bayesian design. Clin Res Cardiol. 2020;109(5):
- (2020) Rationale and design of two randomized sham-controlled trials of catheter-based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN-OFF MED Pivotal) and presence (SPYRAL HTN-ON MED Expansion) of antihypertensive medications: a novel approach using Bayesian design. Clin Res Cardiol. 2020;109(3): 289-302
- (2020) Alcohol-Mediated Renal Denervation Using the Peregrine System Infusion Catheter for Treatment of Hypertension. JACC Cardiovasc Interv. 2020;13(4): 471-484
- (2020) Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020;395(10234): 1444-1451
- (2020) Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020;383(23): 2219-2229
- (2020) Metabolic effects and cardiovascular safety of an oral triple therapy of type 2 diabetes: the metformin, empagliflozin, linagliptin example DIABETOL STOFFWECHS. 2020;15(04): 317-326
- (2020) Resting heart rate and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk analysis from the ONTARGET/TRANSCEND trials. Eur Heart J. 2020;41(2): 231-238
- (2020) Lumen narrowing and increased wall to lumen ratio of retinal microcirculation are valuable biomarkers of hypertension-mediated cardiac damage. Blood Press. 2020;29(2): 70-79
- (2019) Effects of the nitric oxide synthase inhibitor ronopterin (VAS203) on renal function in healthy volunteers. Br J Clin Pharmacol. 2019;85(5): 900-907
- (2019) Effects of renal denervation on blood pressure in hypertensive patients with end-stage renal disease: a single centre experience. Clin Exp Nephrol. 2019;23(6): 749-755
- (2019) Left Ventricular Structure in Patients With Mild-to-Moderate CKD-a Magnetic Resonance Imaging Study. Kidney Int Rep. 2019;4(2): 267-274
- (2019) How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial. Cardiovasc Diabetol. 2019;18(1):
- (2019) Patient preference for therapies in hypertension: a cross-sectional survey of German patients. Clin Res Cardiol. 2019;108(12): 1331-1342
- (2019) Reply. J Hypertens. 2019;37(2):
- (2019) Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk. Eur Heart J. 2019;40(25): 2032-2043
- (2019) [Comments on the guidelines (2018) of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH) on the management of arterial hypertension]. Internist (Berl). 2019;60(4): 424-430
- (2019) [European guidelines for the management of arterial hypertension 2018-what has changed?] Internist (Berl). 2019;60(2): 202-208
- (2019) Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control Following Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial. Circulation. 2019;139(22): 2542-2553
- (2019) Changes in 24-Hour Patterns of Blood Pressure in Hypertension Following Renal Denervation Therapy. Hypertension. 2019;74(2): 244-249
- (2019) Tissue sodium content in patients with type 2 diabetes mellitus. J Diabetes Complications. 2019;33(7): 485-489
- (2019) Renal Denervation for Treating Hypertension: Current Scientific and Clinical Evidence. JACC Cardiovasc Interv. 2019;12(12): 1095-1105
- (2019) Renal Denervation Update From the International Sympathetic Nervous System Summit: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;73(23): 3006-3017
- (2019) Evidence of neurodegeneration in individuals with only mildly elevated blood pressure. J Hypertens. 2019;37(12): 2389-2397
- (2019) [2018 ESC/ESH Guidelines for the management of arterial hypertension]. Kardiol Pol. 2019;77(2): 71-159
- (2019) TREATMENT-BLINDED MEDICATION TITRATION FOR HYPERTENSION CONTROL FOLLOWING RANDOMIZATION TO ENDOVASCULAR ULTRASOUND RENAL DENERVATION OR A SHAM PROCEDURE J Am Coll Cardiol. 2019;73 Suppl 1(9): 1034-1034
- (2019) Implementation of Bayesian Study Design in the SPYRAL HTN-OFF MED Pivotal Trial J Am Coll Cardiol. 2019;74 Suppl B(13): B597-B597
- (2019) Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry Eur Heart J. 2019;40(42): 3474-+
- (2019) SUBGROUP ANALYSIS OF LONG-TERM BLOOD PRESSURE REDUCTION IN THE GLOBAL SYMPLICITY REGISTRY J Am Coll Cardiol. 2019;73 Suppl 1(9): 1723-1723
- (2019) ESC/ESH 2018 Guide on the diagnosis and treatment of arterial hypertension Rev Esp Cardiol. 2019;72(2):
- (2019) Low doses of Intrarenal Bradykinin induce a Monophasic Sympathoinhibitory Response FASEB J. 2019;33 Suppl 1():
- (2019) Different forms of afferent nerve input in cardiac and renal disease in rats? FASEB J. 2019;33 Suppl 1():
- (2019) 2018 ESC/ESH Guidelines for the management of arterial hypertension (vol 39, pg 3021, 2018) Eur Heart J. 2019;40(5): 475-475
- (2019) New data, new studies, new hopes for renal denervation in patients with uncontrolled hypertension. Int J Cardiol Hypertens. 2019;3():
- (2019) Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet. 2019;393(10170): 407-415
- (2018) Renal denervation improves 24-hour central and peripheral blood pressures, arterial stiffness, and peripheral resistance. J Clin Hypertens (Greenwich). 2018;20(2): 366-372
- (2018) Retinal capillary and arteriolar changes in patients with chronic kidney disease. Microvasc Res. 2018;118(): 121-127
- (2018) Percutaneous Creation of a Central Iliac Arteriovenous Anastomosis for the Treatment of Arterial Hypertension. Curr Hypertens Rep. 2018;20(3):
- (2018) Correction to: Percutaneous Creation of a Central Iliac Arteriovenous Anastomosis for the Treatment of Arterial Hypertension. Curr Hypertens Rep. 2018;20(3):
- (2018) Individualised treatment targets in patients with type-2 diabetes and hypertension. Cardiovasc Diabetol. 2018;17(1):
- (2018) Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet. 2018;391(10137): 2335-2345
- (2018) Application of a central iliac arteriovenous coupler device in severe treatment-resistant hypertension: a 3.5-year follow-up. J Hypertens. 2018;36(12): 2471-2477
- (2018) Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120-140 mmHg) and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. Eur Heart J. 2018;39(33): 3105-3114
- (2018) Attenuation of Splanchnic Autotransfusion Following Noninvasive Ultrasound Renal Denervation: A Novel Marker of Procedural Success. J Am Heart Assoc. 2018;7(12):
- (2018) European Society of Hypertension position paper on renal denervation 2018. J Hypertens. 2018;36(10): 2042-2048
- (2018) 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33): 3021-3104
- (2018) Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018;391(10137): 2346-2355
- (2018) Interpretation of noninvasive retinal microvascular studies: the individual source of the automatic full field imaging analysis program has to be taken into account. J Hypertens. 2018;36(11):
- (2018) Early vascular parameters in the micro- and macrocirculation in type 2 diabetes. Cardiovasc Diabetol. 2018;17(1):
- (2018) Blood Pressure Pattern and Target Organ Damage in Patients With Chronic Kidney Disease Hypertension. 2018;72(4): 929-936
- (2018) Secretory Capacity of Pancreatic Beta-Cells Is Enhanced 6 Months After Renal Denervation in Hypertensive Patients. J Am Coll Cardiol. 2018;72(25): 3372-3374
- (2018) [2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH)]. G Ital Cardiol (Rome). 2018;19(11): 3-73
- (2018) 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36(10): 1953-2041
- (2018) THE INFLUENCE OF ANNOYANCE DUE TO NOISE ON RENAL HEMODYNAMIC J Hypertens. 2018;36(): E39-E39
- (2018) DIFFERENT RESPONSE PATTERN TO AIRCRAFT NOISE EXPOSURE IN RENAL VERSUS SYSTEMIC HEMODYNAMIC J Hypertens. 2018;36(): E138-E138
- (2018) COPEPTIN AS A RESEARCH MARKER IN CARDIOVASCULAR DISEASE J Hypertens. 2018;36(): E35-E35
- (2018) EFFECTS OF RENAL DENERVATION ON BLOOD PRESSURE IN PATIENTS WITH END-STAGE RENAL DISEASE: A SINGLE CENTER EXPERIENCE J Hypertens. 2018;36(): E49-E49
- (2018) APPLICATION OF A CENTRAL ILIAC ARTERIOVENOUS COUPLER DEVICE IN SEVERE TREATMENT-RESISTANT ARTERIAL HYPERTENSION: A FOUR-YEAR FOLLOW-UP J Hypertens. 2018;36(): E104-E104
- (2018) Difference in renal parenchymal perfusion after renal denervation comparing treated vs. non-treated arteries Eur Heart J. 2018;39(): 663-663
- (2018) How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Eur Heart J. 2018;39(): 869-869
- (2018) EARLY VASCULAR PARAMETERS IN THE MICRO- AND MACROCIRCULATION IN TYPE 2 DIABETES J Hypertens. 2018;36(): E9-E9
- (2018) RADIANCE-HTN SOLO: A MULTICENTER, RANDOMIZED, SHAM-CONTROLLED STUDY OF RENAL DENERVATION IN PATIENTS WITH UNCONTROLLED HYPERTENSION IN THE ABSENCE OF ANTIHYPERTENSIVE MEDICATIONS J Hypertens. 2018;36(): E238-E238
- (2018) COST-EFFECTIVENESS ANALYSIS OF NEXT GENERATION RENAL DENERVATION THERAPY DEVICES: THRESHOLD ANALYSIS AND PROJECTIONS OF THE SPYRAL HTN-ON MED TRIAL FOR GERMANY Value Health. 2018;21(): S261-S261
- (2018) Predictors of atherosclerotic events in patients on haemodialysis: post hoc analyses from the AURORA study. Nephrol Dial Transplant. 2018;33(1): 102-112
- (2018) Impact of renal denervation on tissue Na+ content in treatment-resistant hypertension. Clin Res Cardiol. 2018;107(1): 42-48
- (2018) Phase II randomized sham-controlled study of renal denervation for individuals with uncontrolled hypertension - WAVE IV. J Hypertens. 2018;36(3): 680-689
- (2018) Retinal vascular resistance in arterial hypertension. Blood Press. 2018;27(2): 82-87
- (2018) Central arteriovenous anastomosis to treat resistant hypertension. Curr Opin Nephrol Hypertens. 2018;27(1): 8-15
- (2018) A multinational clinical approach to assessing the effectiveness of catheter-based ultrasound renal denervation: The RADIANCE-HTN and REQUIRE clinical study designs. Am Heart J. 2018;195(): 115-129
- (2018) SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial. Cardiovasc Diabetol. 2018;17(1): 5
- (2017) Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes. Kidney Int. 2017;91(3): 683-690
- (2017) Skin Sodium Concentration Correlates with Left Ventricular Hypertrophy in CKD. J Am Soc Nephrol. 2017;28(6): 1867-1876
- (2017) Renal artery denervation for treatment of patients with self-reported obstructive sleep apnea and resistant hypertension: results from the Global SYMPLICITY Registry. J Hypertens. 2017;35(1): 148-153
- (2017) Increased Aldosterone Release During Head-Up Tilt in Early Primary Hypertension. Am J Hypertens. 2017;30(5): 484-489
- (2017) A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation. Cardiovasc Diabetol. 2017;16(1): 26
- (2017) Low dose-eplerenone treatment decreases aortic stiffness in patients with resistant hypertension. J Clin Hypertens (Greenwich). 2017;19(7): 669-676
- (2017) Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. Lancet. 2017;389(10085): 2226-2237
- (2017) Proceedings from the 2nd European Clinical Consensus Conference for device-based therapies for hypertension: state of the art and considerations for the future. Eur Heart J. 2017;38(44): 3272-3281
- (2017) Two-year outcome and risk factors for mortality in patients with coronary artery disease and renal failure: The prospective, observational CAD-REF Registry. Int J Cardiol. 2017;243(): 65-72
- (2017) [Arterial Hyper- and Hypotension associated with psychiatric medications: a risk assessment based on the summaries of product characteristics (SmPCs)]. Dtsch Med Wochenschr. 2017;142(16): e100-e107
- (2017) Expertise: No Longer a Sine Qua Non for Guideline Authors? Hypertension. 2017;70(2): 235-237
- (2017) Accuracy of Cuff-Measured Blood Pressure: Systematic Reviews and Meta-Analyses. J Am Coll Cardiol. 2017;70(5): 572-586
- (2017) Expertise: no longer a sine qua non for guideline authors? J Hypertens. 2017;35(8): 1564-1566
- (2017) Low-dose eplerenone decreases left ventricular mass in treatment-resistant hypertension. J Hypertens. 2017;35(5): 1086-1092
- (2017) Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet. 2017;390(10108): 2160-2170
- (2017) Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus. Circulation. 2017;136(12): 1167-1169
- (2017) The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study. Eur Heart J. 2017;38(44): 3308-3317
- (2017) Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease. Eur J Heart Fail. 2017;19(6): 811
- (2017) Relative and Combined Prognostic Importance of On-Treatment Mean and Visit-to-Visit Blood Pressure Variability in ONTARGET and TRANSCEND Patients. Hypertension. 2017;70(5): 938-948
- (2017) Reply. J Hypertens. 2017;35(11): 2327-2328
- (2017) Central Iliac Arteriovenous Anastomosis for Uncontrolled Hypertension: One-Year Results From the ROX CONTROL HTN Trial. Hypertension. 2017;70(6): 1099-1105
- (2017) Retinal capillary rarefaction in patients with untreated mild-moderate hypertension. BMC Cardiovasc Disord. 2017;17(1): 300
- (2017) Non-invasive cardiovascular imaging for evaluating subclinical target organ damage in hypertensive patients: A consensus paper from the European Association of Cardiovascular Imaging (EACVI), the European Society of Cardiology Council on Hypertension, and Eur Heart J Cardiovasc Imaging. 2017;18(9): 945-960
- (2017) Oxidized LDL, statin use, morbidity, and mortality in patients receiving maintenance hemodialysis. Free Radic Res. 2017;51(1): 14-23
- (2017) Noninvasive cardiovascular imaging for evaluating subclinical target organ damage in hypertensive patients: a consensus article from the European Association of Cardiovascular Imaging, the European Society of Cardiology Council on Hypertension and the Eur J Hypertens. 2017;35(9): 1727-1741
- (2017) Secretory Capacity of Pancreatic Beta Cells Is Enhanced 6 Months after Renal Denervation in Hypertensive Patients Diabetes. 2017;66 1(): A65-A65
- (2017) Quality of life and emotional impact of a fixed-dose combination of antihypertensive drugs in patients with uncontrolled hypertension. J Clin Hypertens (Greenwich). 2017;19(2): 126-134
- (2016) Mid-Term Vascular Safety of Renal Denervation Assessed by Follow-up MR Imaging. Cardiovasc Intervent Radiol. 2016;39(3): 426-32
- (2016) Cocoa Flavanol Cardiovascular Effects Beyond Blood Pressure Reduction. J Clin Hypertens (Greenwich). 2016;18(4): 352-8
- (2016) Impaired excitability of renal afferent innervation after exposure to the inflammatory chemokine CXCL1. Am J Physiol Renal Physiol. 2016;310(5): F364-71
- (2016) Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease. Eur J Heart Fail. 2016;18(1): 28-37
- (2016) Baseline Characteristics and Prescription Patterns of Standard Drugs in Patients with Angiographically Determined Coronary Artery Disease and Renal Failure (CAD-REF Registry). PLoS ONE. 2016;11(2): e0148057
- (2016) Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT: rationale for further study on blood pressure targets of antihypertensive treatment after stroke. J Hypertens. 2016;34(3): 393-6
- (2016) Complex reinnervation pattern after unilateral renal denervation in rats. Am J Physiol Regul Integr Comp Physiol. 2016;310(9): R806-18
- (2016) Azilsartan compared to ACE inhibitors in anti-hypertensive therapy: one-year outcomes of the observational EARLY registry. BMC Cardiovasc Disord. 2016;16(1): 56
- (2016) Adherence to Antihypertensive Medication in Treatment-Resistant Hypertension Undergoing Renal Denervation. J Am Heart Assoc. 2016;5(2):
- (2016) Is Azilsartan More Effective in Younger Than in Older Patients? An Explorative Analysis of the Prospective EARLY Registry. J Clin Hypertens (Greenwich). 2016;18(8): 826-7
- (2016) Renal denervation in hypertensive patients not on blood pressure lowering drugs. Clin Res Cardiol. 2016;105(9): 755-62
- (2016) Non-invasive Renal Denervation: Update on External Ultrasound Approaches. Curr Hypertens Rep. 2016;18(6): 48
- (2016) Platelet CD40 contributes to enhanced monocyte chemoattractant protein 1 levels in patients with resistant hypertension. Eur J Clin Invest. 2016;46(6): 564-71
- (2016) Benefits and Risks of Aliskiren Treatment in Patients With Type 2 Diabetes: Analyses of the 3A Registry. J Clin Hypertens (Greenwich). 2016;18(10): 1045-1053
- (2016) Reproducibility of Kidney Perfusion Measurements With Arterial Spin Labeling at 1.5 Tesla MRI Combined With Semiautomatic Segmentation for Differential Cortical and Medullary Assessment. Medicine (Baltimore). 2016;95(11): e3083
- (2016) The Effect of Resting Heart Rate on the New Onset of Microalbuminuria in Patients With Type 2 Diabetes: A Subanalysis of the ROADMAP Study. Medicine (Baltimore). 2016;95(15): e3122
- (2016) Improvement in Retinal Capillary Rarefaction After Valsartan Treatment in Hypertensive Patients. J Clin Hypertens (Greenwich). 2016;18(11): 1112-1118
- (2016) Comparative study of the efficacy of olmesartan/amlodipine vs. perindopril/amlodipine in peripheral blood pressure after missed dose in type 2 diabetes. J Hypertens. 2016;34(2): 359-67
- (2016) Externally Delivered Focused Ultrasound for Renal Denervation. JACC Cardiovasc Interv. 2016;9(12): 1292-9
- (2016) Why in 2016 are patients with hypertension not 100% controlled? A call to action. J Hypertens. 2016;34(8): 1480-8
- (2016) Early Signs of End-Organ Damage in Retinal Arterioles in Patients with Type 2 Diabetes Compared to Hypertensive Patients. Microcirculation. 2016;23(6): 447-55
- (2016) Two-Year Outcomes of Patients Treated With Aliskiren Under Clinical Practice Conditions: Non-Interventional Prospective Study. J Clin Hypertens (Greenwich). 2016;18(7): 647-54
- (2016) Will SPRINT change my practice? SPRINT: a randomised trial of intensive versus standard blood-pressure control. EuroIntervention. 2016;12(6): 809-12
- (2016) Executive Summary of the Joint Position Paper on Renal Denervation of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) and the European Society of Hypertension (ESH). Cardiovasc Intervent Radiol. 2016;39(12): 1681-1683
- (2016) Effects of linagliptin on renal endothelial function in patients with type 2 diabetes: a randomised clinical trial. Diabetologia. 2016;59(12): 2579-2587
- (2016) The effect of renal denervation in moderate treatment-resistant hypertension with confirmed medication adherence. J Hypertens. 2016;34(12): 2475-2479
- (2016) Executive summary of the joint position paper on renal denervation of the Cardiovascular and Interventional Radiological Society of Europe and the European Society of Hypertension. J Hypertens. 2016;34(12): 2303-2304
- (2016) Scientific Data and Transparency of Conflict of Interest Are Important, Not Biased Editorial Without Facts. JACC Cardiovasc Interv. 2016;9(21): 2263
- (2016) Retinal Capillary Rarefaction in Patients with Type 2 Diabetes Mellitus. PLoS ONE. 2016;11(12): e0162608
- (2016) Effect of Arteriovenous Anastomosis on Blood Pressure Reduction in Patients With Isolated Systolic Hypertension Compared With Combined Hypertension. J Am Heart Assoc. 2016;5(12):
- (2016) The Effects of LCZ696 on Left Ventricular Remodeling in Hypertensive Patients - Results of a Double Blind, Randomized, Multicenter Trial Circulation. 2016;134 1(): -
- (2016) The effects of LCZ696 on left ventricular remodeling in hypertensive patients - Results of a double blind, randomized, multicenter trial Eur Heart J. 2016;37 1(): 621-621
- (2016) Effects of Dapagliflozin on Early Alterations of the Micro- and Macrocirculation in Patients with Type 2 Diabetes Diabetes. 2016;65(1): A115-A115
- (2015) Efficacy and Safety of Non-invasive Renal Denervation Study Using Externally Delivered Focused Ultrasound in Severe Resistant Hypertension Circulation. 2015;132 3(): -
- (2015) Individualized Treatment in Patients with Comorbid Type 2 Diabetes and Heart Failure: Insights from the DIALOGUE Registry Diabetes. 2015;64(1): A395-A395
- (2015) The Impact of Overt Vascular Disease in Patients with Comorbid Type 2 Diabetes and Hypertension: Data from the DIALOGUE Registry Diabetes. 2015;64(1): A680-A681
- (2015) Non-invasive Renal Denervation Study Using Externally Delivered Focused Ultrasound in Severe Resistant Hypertension: 1 Year Follow up Results J Am Coll Cardiol. 2015;66 S(15): B40-B40
- (2015) NON-TRADITIONAL CARDIOVASCULAR RISK FACTORS PREDOMINATE IN HEMODIALYSIS PATIENTS WITH PRE-EXISTIN CARDIOVASCULAR DISEASE Nephrol Dial Transplant. 2015;30(3): -
- (2015) EFFECTS OF LINAGLIPTIN ON EARLY ALTERATIONS OF RENAL ENDOTHELIAL FUNCTION IN PATIENTS WITH TYPE-2 DIABETES Nephrol Dial Transplant. 2015;30(3): -
- (2015) Hypertension and Diabetes Der Diabetologe. 2015;11(5): 371-372
- (2015) Blood glucose and blood pressure related treatment target achievement: results of the prospective DIALOGUE registry Diabetologia. 2015;58 1(): S435-S436
- (2015) 24 months follow up of the Luebeck and Erlangen RDN registry: RDN improves 24 h peripheral and central blood pressure as well as 24h-arterial stiffness Eur Heart J. 2015;36 1(): 1055-1055
- (2015) The impact of overt vascular disease in patients with comorbid type-2 diabetes and hypertension: data from the Dialogue registry Eur Heart J. 2015;36 1(): 539-539
- (2015) Achievement of individualized blood pressure and HbA1c targets in patients with hypertension and type-2 diabetes Eur Heart J. 2015;36 1(): 539-539
- (2015) Individualized treatment in patients with comorbid type-2 diabetes and heart failure: insights from the DIALOGUE registry Eur Heart J. 2015;36 1(): 667-667
- (2015) Cost of poor adherence to anti-hypertensive therapy in five European countries. Eur J Health Econ. 2015;16(1): 65-72
- (2015) Circadian rhythm and day to day variability of serum potassium concentration: a pilot study. J Nephrol. 2015;28(2): 165-72
- (2015) Reduced effect of percutaneous renal denervation on blood pressure in patients with isolated systolic hypertension. Hypertension. 2015;65(1): 193-9
- (2015) Aldosterone antagonists and renal denervation: friends or foes? Hypertension. 2015;65(2): 280-2
- (2015) The impact of age on the benefits and risks of aliskiren treatment: analyses of the 3A registry. J Hum Hypertens. 2015;29(5): 316-23
- (2015) Wilder's principle: pre-treatment value determines post-treatment response. Eur Heart J. 2015;36(9): 576-579
- (2015) Olmesartan improves pulse wave velocity and lowers central systolic blood pressure and ambulatory blood pressure in patients with metabolic syndrome. J Clin Hypertens (Greenwich). 2015;17(2): 98-104
- (2015) Resting heart rate is associated with renal disease outcomes in patients with vascular disease: results of the ONTARGET and TRANSCEND studies. J Intern Med. 2015;278(1): 38-49
- (2015) Safety and effectiveness of a fixed-dose combination of olmesartan, amlodipine, and hydrochlorothiazide in clinical practice. Vasc Health Risk Manag. 2015;11(): 1-8
- (2015) Achievement of individualized treatment targets in patients with comorbid type-2 diabetes and hypertension: 6 months results of the DIALOGUE registry. BMC Endocr Disord. 2015;15(1): 23
- (2015) New approaches in the treatment of hypertension. Circ Res. 2015;116(6): 1074-95
- (2015) Effects of renal sympathetic denervation on urinary sodium excretion in patients with resistant hypertension. Clin Res Cardiol. 2015;104(8): 672-8
- (2015) Renal impairment and worsening of renal function in acute heart failure: can new therapies help? The potential role of serelaxin. Clin Res Cardiol. 2015;104(8): 621-31
- (2015) Retinal microperfusion after renal denervation in treatment-resistant hypertensive patients. Clin Res Cardiol. 2015;104(9): 782-9
- (2015) Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design. Eur Heart J. 2015;36(33): 2219-27
- (2015) Central pulse pressure predicts BP reduction after renal denervation in patients with treatment-resistant hypertension. EuroIntervention. 2015;11(1): 110-6
- (2015) First report of the Global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension. Hypertension. 2015;65(4): 766-74
- (2015) [Cardiac effects of hypertension]. Internist (Berl). 2015;56(5): 583-5
- (2015) Renal denervation preserves renal function in patients with chronic kidney disease and resistant hypertension. J Hypertens. 2015;33(6): 1261-6
- (2015) Low resting heart rates are associated with new-onset atrial fibrillation in patients with vascular disease: results of the ONTARGET/TRANSCEND studies. J Intern Med. 2015;278(3): 303-12
- (2015) Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension (the ROX CONTROL HTN study): a randomised controlled trial. Lancet. 2015;385(9978): 1634-41
- (2015) [Renal denervation in refractory hypertension: joint statement of the German hypertension league DHL eV and the German societies of cardiology, angiology, nephrology and radiology]. Dtsch Med Wochenschr. 2015;140(5): 363
- (2015) Systolic blood pressure variation and mean heart rate is associated with cognitive dysfunction in patients with high cardiovascular risk. Hypertension. 2015;65(3): 651-61
- (2015) Managing Treatment-Resistant Patients. High Blood Press Cardiovasc Prev. 2015;22 Suppl 1(): 11-3
- (2015) Renal Denervation for Resistant Hypertension: Past, Present, and Future. Curr Hypertens Rep. 2015;17(8): 65
- (2015) Patients With Newly Diagnosed Hypertension Treated With the Renin Angiotensin Receptor Blocker Azilsartan Medoxomil vs Angiotensin-Converting Enzyme Inhibitors: The Prospective EARLY Registry. J Clin Hypertens (Greenwich). 2015;17(12): 947-53
- (2015) Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. JAMA. 2015;314(9): 884-94
- (2015) Effect of aliskiren on vascular remodelling in small retinal circulation. J Hypertens. 2015;33(12): 2491-9
- (2015) Quality Of Life And Emotional Impact Of A Fixed Dose Combination Of Antihypertensive Drugs In Patients With Uncontrolled Hypertension. Value Health. 2015;18(7): A397
- (2015) 7B.01: FINAL ANALYSIS ON ADHERENCE TO ANTIHYPERTENSIVE MEDICATION IN TREATMENT RESISTANT HYPERTENSION (TRH) UNDERGOING RENAL DENERVATION (RDN). J Hypertens. 2015;33 Suppl 1(): e92
- (2015) The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry. Trials. 2015;16(1): 581
- (2015) Central arteriovenous anastomosis and hypertension - Authors' reply. Lancet. 2015;386(10006): 1821-2
- (2015) 1D.09: APPLICABILITY OF MEASUREMENT OF RENAL PERFUSION USING 1.5 TESLA MRI ARTERIAL SPIN LABELLING. J Hypertens. 2015;33 Suppl 1(): e17
- (2015) Reply to comment on Cost of poor adherence to anti-hypertensive therapy in five European country. Eur J Health Econ. 2015;16(8): 909-11
- (2015) 7D.07: RETINAL ARTERIOLAR STRUCTURE IN PATIENTS WITH PHEOCHROMOCYTOMA. J Hypertens. 2015;33 Suppl 1(): e102
- (2015) 7D.11: RETINAL ARTERIOLAR STRUCTURE IN PATIENTS WITH PRIMARY ALDOSTERONISM. J Hypertens. 2015;33 Suppl 1(): e103
- (2015) 8B.04: RENAL ARTERY DENERVATION FOR TREATMENT OF HYPERTENSIVE PATIENTS WITH OR WITHOUT OBSTRUCTIVE SLEEP APNEA AND RESISTANT HYPERTENSION: RESULTS FROM THE GLOBAL SYMPLICITY REGISTRY. J Hypertens. 2015;33 Suppl 1(): e108
- (2015) 4A.01: LONG-TERM EFFECTS OF RENAL ARTERY DENERVATION IN REAL WORLD PATIENTS WITH UNCONTROLLED HYPERTENSION FROM THE GLOBAL SYMPLICITY REGISTRY. J Hypertens. 2015;33 Suppl 1(): e49
- (2015) LB02.02: EFFECT OF ARTERIOVENOUS ANASTOMOSIS ON BLOOD PRESSURE REDUCTION IN PATIENTS WITH ISOLATED SYSTOLIC HYPERTENSION COMPARED TO COMBINED HYPERTENSION. J Hypertens. 2015;33 Suppl 1(): e85
- (2014) Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy. Am J Nephrol. 2014;40(6): 572-81
- (2014) Urinary albumin excretion from spot urine samples predict all-cause and stroke mortality in africans. Am J Hypertens. 2014;27(6): 811-8
- (2014) 2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Press. 2014;23(1): 3-16
- (2014) Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes. Cardiovasc Diabetol. 2014;13(): 19
- (2014) Response to letter regarding article, "ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension". Circulation. 2014;129(20): e500-1
- (2014) Clinical impact of patient adherence to a fixed-dose combination of olmesartan, amlodipine and hydrochlorothiazide. Clin Drug Investig. 2014;34(6): 403-11
- (2014) Effects of folic acid on renal endothelial function in patients with diabetic nephropathy: results from a randomized trial. Clin Sci (Lond). 2014;127(7): 499-505
- (2014) A guide for easy- and difficult-to-treat hypertension. Int J Cardiol. 2014;172(1): 17-22
- (2014) Improvement of albuminuria after renal denervation. Int J Cardiol. 2014;173(2): 311-5
- (2014) Daytime systolic ambulatory blood pressure with a two-step switch from candesartan to olmesartan monotherapy and the fixed-dose combination of olmesartan/amlodipine in patients with uncontrolled essential hypertension (SEVICONTROL-2). J Clin Hypertens (Greenwich). 2014;16(1): 41-6
- (2014) The International Society of Hypertension and World Hypertension League call on governments, nongovernmental organizations and the food industry to work to reduce dietary sodium. J Hypertens. 2014;32(2): 446-7
- (2014) Hypertension: How should data from SYMPLICITY HTN-3 be interpreted? Nat Rev Cardiol. 2014;11(7): 375-6
- (2014) Renal denervation-implications for chronic kidney disease. Nat Rev Nephrol. 2014;10(6): 305-13
- (2014) Dialysis cardiovascular complications 2. Nephrol Dial Transplant. 2014;29 Suppl 3(): iii481-iii490
- (2014) Renal denervation. Nephrol Dial Transplant. 2014;29 Suppl 3(): iii9-iii10
- (2014) Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial. Eur Heart J. 2014;35(26): 1752-9
- (2014) Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline: a review of available trial evidence. J Hypertens. 2014;32(9): 1741-50
- (2014) Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient: design of the European Society of Hypertension-Chinese Hypertension League Stroke in Hypertension Optimal Treatment randomize J Hypertens. 2014;32(9): 1888-97
- (2014) [Dialysis and ultrafiltration therapy in patients with cardio-renal syndrome: recommendations of the working group "heart-kidney" of the German Cardiac Society and the German Society of Nephrology]. Dtsch Med Wochenschr. 2014;139(7): e1-8
- (2014) From SYMPLICITY HTN-3 to the Renal Denervation Global Registry: where do we stand and where should we go? EuroIntervention. 2014;10(1): 21-3
- (2014) The World Hypertension League and International Society of Hypertension call on governments, nongovernmental organizations, and the food industry to work to reduce dietary sodium. J Clin Hypertens (Greenwich). 2014;16(2): 99-100
- (2014) Impact of telmisartan on cardiovascular outcome in hypertensive patients at high risk: a Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease subanalysis. J Hypertens. 2014;32(6): 1334-41
- (2014) First experience in analysing pulsatile retinal capillary flow and arteriolar structural parameters measured noninvasively in hypertensive patients. J Hypertens. 2014;32(11): 2246-52; discussion 2252
- (2014) Invasive treatment of resistant hypertension: present and future. Curr Hypertens Rep. 2014;16(11): 488
- (2014) Disproportional decrease in office blood pressure compared with 24-hour ambulatory blood pressure with antihypertensive treatment: dependency on pretreatment blood pressure levels. Hypertension. 2014;64(5): 1067-72
- (2014) 1-Year outcomes of hypertension management in 13,000 outpatients under practice conditions: Prospective 3A registry. Int J Cardiol. 2014;176(3): 589-94
- (2014) Prevention of electrocardiographic left ventricular remodeling by the angiotensin receptor blocker olmesartan in patients with type 2 diabetes. J Hypertens. 2014;32(11): 2267-76; discussion 2276
- (2014) Renal denervation-a valid treatment option despite SYMPLICITY HTN-3. Nat Rev Cardiol. 2014;11(11): 638
- (2014) Mortality and morbidity in relation to changes in albuminuria, glucose status and systolic blood pressure: an analysis of the ONTARGET and TRANSCEND studies. Diabetologia. 2014;57(10): 2019-29
- (2014) Dose-dependent arterial destiffening and inward remodeling after olmesartan in hypertensives with metabolic syndrome. Hypertension. 2014;64(4): 709-16
- (2014) Achievement of individualised HbA(1c) treatment targets in patients with type 2 diabetes and comorbid hypertension in a real world setting: results of the DIALOGUE registry Diabetologia. 2014;57(1): S133-S133
- (2014) Achievement of individualised blood pressure targets in patients with hypertension and comorbid type 2 diabetes in a real world setting: results of the DIALOGUE registry Diabetologia. 2014;57(1): S94-S95
- (2014) RISK FACTORS FOR CARDIOVASCULAR EVENTS AND ALL-CAUSE MORTALITY IN DIABETIC HEMODIALYSIS PATIENTS Nephrol Dial Transplant. 2014;29 3(): 487-487
- (2014) Diagnosis and treatment of resistant hypertension. Blood Press. 2014;23(4): 193-9
- (2014) Heart rate and blood pressure interactions in the development of erectile dysfunction in high-risk cardiovascular patients. Eur J Prev Cardiol. 2014;21(3): 272-80
- (2014) What the interventionalist should know about renal denervation in hypertensive patients: a position paper by the ESH WG on the interventional treatment of hypertension EuroIntervention. 2014;9(9): 27-35
- (2014) IMPROVEMENT OF ALBUMINURIA AFTER RENAL DENERVATION Nephrol Dial Transplant. 2014;29 3(): 9-9
- (2014) Renal protection by low dose irbesartan in diabetic nephropathy is paralleled by a reduction of inflammation, not of endoplasmic reticulum stress Biochim Biophys Acta Mol Basis Dis. 2014;1842(4): 558-565
- (2014) IMPROVEMENT OF ALBUMINURIA AFTER RENAL DENERVATION J Am Coll Cardiol. 2014;63 S(12): A2055-A2055
- (2014) RENAL DENERVATION STOPS THE DECLINE OF RENAL FUNCTION IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND RESISTANT HYPERTENSION Nephrol Dial Transplant. 2014;29 3(): 10-10
- (2013) Renal Denervation via Catheter-Based Delivery of Radiofrequency Energy Significantly Reduces Blood Pressure in Subjects With Severe Treatment-Resistant Hypertension: Long-Term Results From the Symplicity HTN Clinical Trials Circulation. 2013;128 S(22): -
- (2013) LV remodelling in patients with type 2 diabetes: determinants of the beneficial effect of olmesartan Diabetologia. 2013;56(1): S38-S38
- (2013) Poor glycaemic control is related with increased nitric oxide activity within the renal circulation of patients with type 2 diabetes mellitus Diabetologia. 2013;56(1): S473-S473
- (2013) Prognostic impact of treatment resistant hypertension on clinical events during 2-year follow-up in outpatients with diabetes and hypertension: results of the 3A Registry Diabetologia. 2013;56(1): S99-S99
- (2013) Ambulatory blood pressure changes and predictors of response in patients undergoing renal sympathetic denervation Eur Heart J. 2013;34(1): 495-495
- (2013) Increased Intrarenal CGRP Release From Afferent Renal Nerves Is Accompanied By Decreased Afferent Electric Activity Hypertension. 2013;62 S(3): -
- (2013) Reduced Firing Activity of Afferent Renal Innervation in the 2kidney/1clip Model of Hypertension Hypertension. 2013;62 S(3): -
- (2013) Persistent and Safe Blood Pressure Lowering Effects of Renal Artery Denervation: Three Year Follow-up From the Symplicity HTN-2 Trial J Am Coll Cardiol. 2013;62 1(18): B19-B19
- (2013) Clinical and Procedural Outcomes of Renal Artery Denervation In Real World Patients with Hypertension: An Update From the Global SYMPLICITY Registry J Am Coll Cardiol. 2013;62 1(18): B19-B20
- (2013) The guidelines of ESH/ESC Guidelines for hypertension in 2013 Kardiol Pol. 2013;71 3(): S27-S116
- (2013) Frailty as clinically relevant Parameters in elderly Patients with arterial Hypertension - the FOHYP Study: Rationale and Study Design Z Gerontol Geriatr. 2013;46(1): 31-31
- (2013) Update hypertension Der Diabetologe. 2013;9(5): 373-379
- (2013) Diet and kidney disease in high-risk individuals with type 2 diabetes mellitus. JAMA Intern Med. 2013;173(18): 1682-92
- (2013) Are physicians underestimating the challenges of hypertension management? Results from the Supporting Hypertension Awareness and Research Europe-wide (SHARE) survey. Eur J Prev Cardiol. 2013;20(5): 786-92
- (2013) Optimizing blood pressure control in hypertension: The need to use ABPM. Blood Press. 2013;22(2): 65-72
- (2013) 25-Hydroxyvitamin D insufficiency is associated with impaired renal endothelial function and both are improved with rosuvastatin treatment. Clin Res Cardiol. 2013;102(4): 299-304
- (2013) Catheter-Based Renal Nerve Ablation and Centrally Generated Sympathetic Activity in Difficult-to-Control Hypertensive Patients: Prospective Case Series. Hypertension. 2013;61(2): e17
- (2013) 23Na Magnetic Resonance Imaging-Determined Tissue Sodium in Healthy Subjects and Hypertensive Patients. Hypertension. 2013;61(3): 635-40
- (2013) Determinants of Cardiovascular Risk in Haemodialysis Patients: Post hoc Analyses of the AURORA Study. Am J Nephrol. 2013;37(2): 144-51
- (2013) Effects of manidipine vs. amlodipine on intrarenal haemodynamics in patients with arterial hypertension. Br J Clin Pharmacol. 2013;75(1): 129-35
- (2013) Vascular and renal hemodynamic changes after renal denervation. Clin J Am Soc Nephrol. 2013;8(7): 1195-201
- (2013) Central pulse pressure is an independent determinant of vascular remodeling in the retinal circulation. Hypertension. 2013;61(6): 1340-5
- (2013) Feasibility of catheter-based renal nerve ablation and effects on sympathetic nerve activity and blood pressure in patients with end-stage renal disease. Int J Cardiol. 2013;168(3): 2214-20
- (2013) Ambulatory blood pressure monitoring: Is it mandatory for blood pressure control in treated hypertensive patients?: Prospective observational study. Int J Cardiol. 2013;168(3): 2255-63
- (2013) Patients with treatment-resistant hypertension report increased stress and anxiety: a worldwide study. J Hypertens. 2013;31(3): 610-5; discussion 615
- (2013) Haemoglobin and vascular function in the human retinal vascular bed. J Hypertens. 2013;31(4): 775-81
- (2013) Clinical situations associated with difficult-to-control hypertension. J Hypertens. 2013;31 Suppl 1(): S3-8
- (2013) Cardiac ablation and renal denervation systems have distinct purposes and different technical requirements. JACC Cardiovasc Interv. 2013;6(3): 314
- (2013) Sensory renal innervation: a kidney-specific firing activity due to a unique expression pattern of voltage-gated sodium channels? Am J Physiol Renal Physiol. 2013;304(5): F491-7
- (2013) Local application of tropicamide 0.5% reduces retinal capillary blood flow. Blood Press. 2013;22(6): 371-6
- (2013) Ruling out secondary causes of hypertension. EuroIntervention. 2013;9 Suppl R(): R21-8
- (2013) Updated ESH position paper on interventional therapy of resistant hypertension. EuroIntervention. 2013;9 Suppl R(): R58-66
- (2013) EARLY Treatment with azilsartan compared to ACE-inhibitors in anti-hypertensive therapy - rationale and design of the EARLY hypertension registry. BMC Cardiovasc Disord. 2013;13(1): 46
- (2013) 2013 ESH/ESC Guidelines for the management of arterial hypertension. Blood Press. 2013;22(4): 193-278
- (2013) Does renal artery supply indicate treatment success of renal denervation? Cardiovasc Intervent Radiol. 2013;36(4): 987-91
- (2013) Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation. 2013;128(2): 132-40
- (2013) The sympathetic nervous system in chronic kidney disease. Curr Hypertens Rep. 2013;15(4): 370-6
- (2013) 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28): 2159-219
- (2013) Renal denervation in moderate treatment-resistant hypertension. J Am Coll Cardiol. 2013;62(20): 1880-6
- (2013) Interpreting treatment-induced blood pressure reductions measured by ambulatory blood pressure monitoring. J Hum Hypertens. 2013;27(12): 715-20
- (2013) 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7): 1281-357
- (2013) Review of direct renin inhibition by aliskiren. J Renin Angiotensin Aldosterone Syst. 2013;14(3): 193-6
- (2013) Safety, tolerability, and efficacy of a fixed-dose combination of olmesartan 40 mg and hydrochlorothiazide 12.5/25 mg in daily practice. Vasc Health Risk Manag. 2013;9(): 475-83
- (2013) The Coronary Artery Disease and Renal Failure (CAD-REF) registry: trial design, methods, and aims. Am Heart J. 2013;166(3): 449-56
- (2013) Poor glycemic control is related to increased nitric oxide activity within the renal circulation of patients with type 2 diabetes. Diabetes Care. 2013;36(12): 4071-5
- (2013) RELAX-AHF: consistency across subgroups and new hypotheses generated. Eur Heart J. 2013;34(40): 3100-1
- (2013) International expert consensus statement: percutaneous transluminal renal denervation for the treatment of resistant hypertension. J Am Coll Cardiol. 2013;62(22): 2031-45
- (2013) Blood pressure and retinal small arteries. J Hypertens. 2013;31(10): 1946-7
- (2013) Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease. Am Heart J. 2013;166(2): 306-314.e7
- (2013) Rationale and design of a large registry on renal denervation: the Global SYMPLICITY registry. EuroIntervention. 2013;9(4): 484-92
- (2013) An update on telmisartan/hydrochlorothiazide combinations for the management of hypertensive patients with additional cardiovascular risk factors. Expert Rev Cardiovasc Ther. 2013;11(6): 673-82
- (2013) Daytime Systolic Ambulatory Blood Pressure With a Direct Switch Between Candesartan Monotherapy and the Fixed-Dose Combination Olmesartan/Amlodipine in Patients With Uncontrolled Essential Hypertension (SEVICONTROL-1) J Clin Hypertens. 2013;15(11): 815-819
- (2013) 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC) J Hypertens. 2013;31(10): 1925-1938
- (2013) HOW EFFECTIVE IS RENAL DENERVATION IN LESS SEVERE TREATMENT RESISTANT HYPERTENSION? J Am Coll Cardiol. 2013;61 S(10): E1385-E1385
- (2012) [Hypertensive crisis]. MMW Fortschr Med. 2012;154(8): 56-7
- (2012) [Diagnosis, implication, prevention and treatment of microalbuminuria]. Dtsch Med Wochenschr. 2012;137(27): 1409-16; quiz 1417-8
- (2012) Impaired increase of retinal capillary blood flow to flicker light exposure in arterial hypertension. Hypertension. 2012;60(3): 871-6
- (2012) Guideline Adherence in Cardiovascular Risk Assessment and Analysis in 15,000 Hypertensive German Patients in Real Life: Results of the Prospective 3A Registry. J Clin Hypertens (Greenwich). 2012;14(8): 496-501
- (2012) Dual RAAS suppression: recent developments and implications in light of the ALTITUDE study. J Renin Angiotensin Aldosterone Syst. 2012;13(3): 409-12
- (2012) Comparison of two noninvasive devices for measurement of central systolic blood pressure with invasive measurement during cardiac catheterization. J Clin Hypertens (Greenwich). 2012;14(9): 575-9
- (2012) Role of neuroendocrine activation for left ventricular hypertrophy in hypertension. J Hypertens. 2012;30(10): 1917-9
- (2012) Renal denervation in a hypertensive patient with end-stage renal disease and small arteries: a direction for future research. J Clin Hypertens (Greenwich). 2012;14(11): 799-801
- (2012) Achievement of recommended glucose and blood pressure targets in patients with type 2 diabetes and hypertension in clinical practice - study rationale and protocol of DIALOGUE. Cardiovasc Diabetol. 2012;11(): 148
- (2012) Renal Sympathetic Denervation for Treatment of Drug-Resistant Hypertension: One-Year Results From the Symplicity HTN-2 Randomized, Controlled Trial. Circulation. 2012;126(25): 2976-2982
- (2012) [The role of retinal microcirculation in hypertension]. Dtsch Med Wochenschr. 2012;137(48): 2500-4
- (2012) Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: analysis of the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects With Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in Combinatio Circulation. 2012;126(8): 934-41
- (2012) Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. Hypertension. 2012;60(2): 419-24
- (2012) Current status of renal denervation in resistant hypertension. J Am Soc Hypertens. 2012;6(6): 414-6
- (2012) The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841): 581-90
- (2012) Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS ONE. 2012;7(1): e29849
- (2012) Prognostic model for total mortality in patients with haemodialysis from the Assessments of Survival and Cardiovascular Events (AURORA) study. J Intern Med. 2012;271(5): 463-71
- (2012) Reversibility of the effects of aliskiren in the renal versus systemic circulation. Clin J Am Soc Nephrol. 2012;7(2): 258-64
- (2012) (23)Na magnetic resonance imaging of tissue sodium. Hypertension. 2012;59(1): 167-72
- (2012) Tonic postganglionic sympathetic inhibition induced by afferent renal nerves? Hypertension. 2012;59(2): 467-76
- (2012) Postchallenge hyperglycemia is closely related with early vascular damage in overweight and obese patients. J Hypertens. 2012;30(1): 147-52
- (2012) Real-life treatment patterns, compliance, persistence, and medication costs in patients with hypertension in Germany. J Med Econ. 2012;15(1): 155-65
- (2012) Influence of blood flow on arteriolar wall-to-lumen ratio in the human retinal circulation in vivo. Microvasc Res. 2012;83(2): 111-7
- (2012) Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment. Position paper of the Working Group 'Hypertension Arrhythmias and Thrombosis' of the European Society of Hypertension. J Hypertens. 2012;30(2): 239-252
- (2012) [Chronobiology of blood pressure and chronopharmacotherapy of arterial hypertension]. Dtsch Med Wochenschr. 2012;137(7): 317-21
- (2012) Salt intake determines retinal arteriolar structure in treatment resistant hypertension independent of blood pressure. Atherosclerosis. 2012;222(1): 235-40
- (2012) Effect of the rs168924 Single-Nucleotide Polymorphism in the SLC6A2 Catecholamine Transporter Gene on Blood Pressure in Caucasians. J Clin Hypertens (Greenwich). 2012;14(5): 293-8
- (2012) Salt and hypertension: is salt dietary reduction worth the effort? Am J Med. 2012;125(5): 433-9
- (2012) Microalbuminuria independently correlates to cardiovascular comorbidity burden in patients with hypertension. Clin Res Cardiol. 2012;101(9): 761-6
- (2012) Aliskiren for the treatment of essential hypertension under real-life practice conditions: design and baseline data of the prospective 3A registry. Int J Clin Pract. 2012;66(3): 251-61
- (2012) ESH position paper: renal denervation - an interventional therapy of resistant hypertension. J Hypertens. 2012;30(5): 837-41
- (2012) Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and difficult to treat arterial hypertension. J Hypertens. 2012;30(6): 1047-1055
- (2012) Wall-to-lumen ratio of retinal arterioles: a reproducible, valid and noninvasive approach for evaluation of early arteriolar changes in arterial hypertension in vivo. J Hypertens. 2012;30(6): 1108-10
- (2012) Reliability of retinal microcirculation measurements by scanning laser Doppler flowmetry in humans. J Hypertens. 2012;30(6): 1266
- (2012) Rosuvastatin improves pulse wave reflection by restoring endothelial function. Microvasc Res. 2012;84(1): 60-4
- (2012) Barriers to cardiovascular risk prevention and management in Germany - an analysis of the EURIKA study. Vasc Health Risk Manag. 2012;8(): 177-86
- (2011) Efficacy and safety of olmesartan medoxomil plus amlodipine in age, gender and hypertension severity defined subgroups of hypertensive patients. J Hum Hypertens. 2011;25(6): 354-63
- (2011) Folic Acid Treatment Normalizes NOS-Dependence of Vascular Tone in the Metabolic Syndrome. Obesity (Silver Spring). 2011;19(5): 960-7
- (2011) Basal nitric oxide activity is an independent determinant of arteriolar structure in the human retinal circulation. J Hypertens. 2011;29(1): 123-9
- (2011) Reduction in Basal nitric oxide activity causes albuminuria. Diabetes. 2011;60(2): 572-6
- (2011) Serum levels of the Th1 chemoattractant interferon-gamma-inducible protein (IP) 10 are elevated in patients with essential hypertension. Hypertens Res. 2011;34(4): 484-8
- (2011) New software analyses increase the reliability of measurements of retinal arterioles morphology by scanning laser Doppler flowmetry in humans. J Hypertens. 2011;29(4): 777-82
- (2011) Renal artery denervation for the treatment of hypertension: opening up new horizons. Cardiovasc Intervent Radiol. 2011;34(3): 442-4
- (2011) Telmisartan in incipient and overt diabetic renal disease. J Nephrol. 2011;24(3): 263-73
- (2011) Association of (pro)renin receptor gene polymorphism with blood pressure in Caucasian men. Pharmacogenet Genomics. 2011;21(6): 347-9
- (2011) Renal protection with angiotensin receptor blockers: where do we stand. J Nephrol. 2011;24(5): 569-80
- (2011) Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011;364(10): 907-17
- (2011) [Comparison of Early Retinal Microvascular Changes and Microalbuminuria as Indicators for Increased Cardioascular Risk]. Klin Monatsbl Augenheilkd. 2011;228(11): 1003-8
- (2011) [Fixed dose combination of an ARB calcium antagonist lowers blood pressure effectively and improves quality of life]. MMW Fortschr Med. 2011;153 Suppl (): 33-40
- (2011) Rosuvastatin in Diabetic Hemodialysis Patients. J Am Soc Nephrol. 2011;22(7): 1335-1341
- (2011) The Fc? receptor IIA R131H gene polymorphism is associated with endothelial function in patients with hypercholesterolaemia. Atherosclerosis. 2011;218(2): 411-5
- (2011) Response to Comment on: Ott et al. Reduction in Basal Nitric Oxide Activity Causes Albuminuria. Diabetes 2011;60:572-576. Diabetes. 2011;60(8): e22
- (2011) Changes in Albuminuria Predict Mortality and Morbidity in Patients with Vascular Disease. J Am Soc Nephrol. 2011;22(7): 1353-1364
- (2011) Cerebral Microangiopathy in Treatment-Resistant Hypertension. J Clin Hypertens (Greenwich). 2011;13(8): 582-587
- (2011) The renaissance of the retinal microvascular network assessment in hypertension: new challenges. J Hypertens. 2011;29(7): 1289-91
- (2011) Physician attitudes to blood pressure control: findings from the Supporting Hypertension Awareness and Research Europe-wide survey. J Hypertens. 2011;29(8): 1633-1640
- (2011) Effects of statin treatment on endothelial function, oxidative stress and inflammation in patients with arterial hypertension and normal cholesterol levels. J Hypertens. 2011;29(9): 1757-64
- (2011) Cerebral Microangiopathy in Treatment-Resistant Hypertension J Clin Hypertens. 2011;13(8): 582-587
- (2011) Remodeling of retinal small arteries in hypertension. Am J Hypertens. 2011;24(12): 1267-73
- (2011) Beyond salt: lifestyle modifications and blood pressure. Eur Heart J. 2011;32(24): 3081-7
- (2011) Validation of a therapeutic scheme for the treatment of resistant hypertension. J Am Soc Hypertens. 2011;5(6): 498-504
- (2011) Urinary sodium and potassium excretion and risk of cardiovascular events. JAMA. 2011;306(20): 2229-38
- (2010) Smoking is associated with a high prevalence of microalbuminuria in hypertensive high-risk patients: data from I-SEARCH. Clin Res Cardiol. 2010;99(12): 825-32
- (2010) Improvement of hypertension management by structured physician education and feedback system: cluster randomized trial. Eur J Cardiovasc Prev Rehabil. 2010;17(3): 271-9
- (2010) Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET. Nephrol Dial Transplant. 2010;25(3): 967-76
- (2010) Measurement of kidney perfusion by magnetic resonance imaging: comparison of MRI with arterial spin labeling to para-aminohippuric acid plasma clearance in male subjects with metabolic syndrome. Nephrol Dial Transplant. 2010;25(4): 1126-33
- (2010) Aliskiren monotherapy does not cause paradoxical blood pressure rises: meta-analysis of data from 8 clinical trials. Hypertension. 2010;55(1): 54-60
- (2010) Renal resistive index in addition to low-grade albuminuria complements screening for target organ damage in therapy-resistant hypertension. J Hypertens. 2010;28(3): 608-14
- (2010) Renal resistive index--a valid tool to assess renal endothelial function in humans? Nephrol Dial Transplant. 2010;25(6): 1869-74
- (2010) The Role of Fixed-Dose Combination Therapy with Drugs that Target the Renin-Angiotensin System in the Hypertension Paradigm. Clin Exp Hypertens. 2010;32(1): 35-42
- (2010) Telmisartan and hydrochlorothiazide combination therapy for the treatment of hypertension. Curr Med Res Opin. 2010;26(4): 879-87
- (2010) Angiotensin II-type 2 receptor: emerging target for cardiovascular protection. Am J Hypertens. 2010;23(3): 220
- (2010) Relation of the first hypertension-associated event with medication, compliance and persistence in naïve hypertensive patients after initiating monotherapy. Int J Clin Pharmacol Ther. 2010;48(3): 173-83
- (2010) [Arterial stiffness and pulse wave analysis] Dtsch Med Wochenschr. 2010;135 Suppl (): S4-14
- (2010) Nitric oxide and reactive hyperemia: role of location and duration of ischemia. Am J Hypertens. 2010;23(8): 865-9
- (2010) Dihydropyridine calcium antagonists are associated with increased albuminuria in treatment-resistant hypertensives. J Nephrol. 2010;23(5): 563-8
- (2010) Role of the angiotensin II type 2 receptor gene (+1675G/A) polymorphism on left ventricular hypertrophy and geometry in treated hypertensive patients. J Hypertens. 2010;28(6): 1221-9
- (2010) Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a meta-analysis. J Am Coll Cardiol. 2010;55(21): 2299-307
- (2010) Agreement within Europe about antihypertensive treatment and education - results from the European Society of Hypertension questionnaire. J Hypertens. 2010;28(7): 1593-4
- (2010) Urinary proteomic diagnosis of coronary artery disease: identification and clinical validation in 623 individuals. J Hypertens. 2010;28(11): 2316-2322
- (2010) Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis (vol 360, pg 1395, 2009) N Engl J Med. 2010;362(15): 1450-1450
- (2010) Effectiveness and tolerability of a fixed-dose combination of olmesartan and amlodipine in clinical practice. Vasc Health Risk Manag. 2010;6(): 803-11
- (2010) Change in Augmentation Index during NOS Inhibition, an Index of Basal NO Production, Is an Independent Determinant of Large-Artery Function. Kidney Blood Press Res. 2010;33(5): 343-51
- (2010) Improving quality of life in hypertension management using a fixed-dose combination of olmesartan and amlodipine in primary care. Expert Opin Pharmacother. 2010;11(17): 2779-90
- (2010) Urinary collagen fragments are significantly altered in diabetes: a link to pathophysiology. PLoS ONE. 2010;5(9):
- (2010) Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol. 2010;21(12): 2151-6
- (2010) Renal protection in diabetes: lessons from ONTARGET. Cardiovasc Diabetol. 2010;9(): 60
- (2010) Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376(9756): 1903-9
- (2010) End organ damage in hypertension. Dtsch Arztebl Int. 2010;107(49): 866-73
- (2009) Elevated VEGF-plasma levels in young patients with mild essential hypertension. Eur J Clin Invest. 2009;39(1): 31-6
- (2009) Renal vascular endothelial function in hypertensive patients with type 2 diabetes mellitus. Am J Kidney Dis. 2009;53(2): 281-9
- (2009) Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. Circulation. 2009;119(3): 417-25
- (2009) Cardiovascular disease in patients with renal disease: the role of statins. Curr Med Res Opin. 2009;25(1): 271-85
- (2009) Statin treatment reduces glomerular inflammation and podocyte damage in rat deoxycorticosterone-acetate-salt hypertension. J Hypertens. 2009;27(2): 376-85
- (2009) The role of statins in the treatment of the metabolic syndrome. Curr Hypertens Rep. 2009;11(2): 143-9
- (2009) Fixed-dose manidipine/delapril versus losartan/hydrochlorothiazide in hypertensive patients with type 2 diabetes and microalbuminuria. Adv Ther. 2009;26(3): 313-24
- (2009) Wall-to-lumen ratio of retinal arterioles and arteriole-to-venule ratio of retinal vessels in patients with cerebrovascular damage. Invest Ophthalmol Vis Sci. 2009;50(9): 4351-9
- (2009) The cardiac MRI substudy to ongoing telmisartan alone and in combination with ramipril global endpoint trial/telmisartan randomized assessment study in ACE-intolerant subjects with cardiovascular disease: analysis protocol and baseline characteristics. Clin Res Cardiol. 2009;98(7): 421-33
- (2009) [Optimal therapy of diabetic nephropathy: AVOID Study (Aliskiren in the evaluation of proteinuria in diabetes)] Internist (Berl). 2009;50(7): 895-6
- (2009) Risk prediction in subjects with high-normal blood pressure. J Hypertens. 2009;27(6): 1126-8
- (2009) Wall-to-lumen ratio of retinal arterioles as a tool to assess vascular changes. Hypertension. 2009;54(2): 384-7
- (2009) Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: sub-analysis of a 52-week, randomized, double-blind trial. J Hypertens. 2009;27(7): 1493-501
- (2009) Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14): 1395-407
- (2009) Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertension. J Hypertens. 2009;27(4): 673-9
- (2009) [Antihypertensive therapy] MMW Fortschr Med. 2009;151(14): 95-8; quiz 99
- (2009) Is a shared decision-making approach effective in improving hypertension management? J Clin Hypertens (Greenwich). 2009;11(5): 266-70
- (2009) Gender is related to alterations of renal endothelial function in type 2 diabetes. Nephrol Dial Transplant. 2009;24(11): 3354-9
- (2009) [Hypertension and diastolic dysfunction] MMW Fortschr Med. 2009;151(23): 41-3
- (2009) Effect of telmisartan on renal outcomes: a randomized trial. Ann Intern Med. 2009;151(1): 1-10, W1-2
- (2009) Hypertension and atrial fibrillation with emphasis on prevention Blood Press. 2009;18(3): 94-98
- (2009) Wall-to-lumen ratio of retinal arterioles is related with urinary albumin excretion and altered vascular reactivity to infusion of the nitric oxide synthase inhibitor N-monomethyl-L-arginine. J Hypertens. 2009;27(11): 2201-8
- (2009) Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Circulation. 2009;120(14): 1380-9
- (2009) Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27(11): 2121-2158
- (2009) Rosuvastatin does not affect intrarenal hemodynamics in patients with hypercholesterolemia. J Nephrol. 2009;22(5): 675-81
- (2009) Angiotensin blockade to reduce microvascular damage in diabetes mellitus. Dtsch Arztebl Int. 2009;106(34-35): 556-62
- (2009) Hypertension and Diabetes: what are the pros to treating early surrogates? Diabetes Care. 2009;32 Suppl 2(): S294-7
- (2009) Significance of initial blood pressure and comorbidity for the efficacy of a fixed combination of an angiotensin receptor blocker and hydrochlorothiazide in clinical practice. Vasc Health Risk Manag. 2009;5(): 991-1000
- (2009) Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press. 2009;18(6): 308-47
- (2009) Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]). Am J Cardiol. 2009;104(11): 1484-9
- (2009) [Renal nerve ablation: innovative therapy for treatment of resistant hypertension] MMW Fortschr Med. 2009;151(42): 52-3
- (2008) (Pro)renin receptor peptide inhibitor "handle-region" peptide does not affect hypertensive nephrosclerosis in goldblatt rats. Hypertension. 2008;51(3): 676-81
- (2008) Basal nitric oxide synthase activity is a major determinant of glomerular haemodynamics in humans. J Hypertens. 2008;26(1): 110-6
- (2008) A promoter polymorphism of the alpha 8 integrin gene and the progression of autosomal-dominant polycystic kidney disease. Nephron Clin Pract. 2008;108(3): c169-75
- (2008) Impact of New-Onset Diabetes Mellitus on Development of Atrial Fibrillation and Heart Failure in High-Risk Hypertension (from the VALUE Trial). Am J Cardiol. 2008;101(5): 634-8
- (2008) Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J Hypertens. 2008;26(3): 403-11
- (2008) Effects of angiotensin II type 1-receptor blockade on retinal endothelial function. J Hypertens. 2008;26(3): 516-22
- (2008) Response to analysis of carotid and ophthalmic flow velocity waveforms Hypertension. 2008;51(3): E19-E19
- (2008) Efficacy of manidipine/delapril versus losartan/hydrochlorothiazide fixed combinations in patients with hypertension and diabetes. J Hypertens. 2008;26(4): 813-8
- (2008) Effect of angiotensin receptor blockade on central haemodynamics in essential hypertension: results of a randomised trial. J Renin Angiotensin Aldosterone Syst. 2008;9(1): 49-56
- (2008) Left ventricular hypertrophy and clinical outcomes in hypertensive patients. Am J Hypertens. 2008;21(5): 500-8
- (2008) Blood pressure versus direct mineralocorticoid effects on kidney inflammation and fibrosis in DOCA-salt hypertension. Nephrol Dial Transplant. 2008;23(11): 3456-63
- (2008) Renin inhibitors, clinical experience. J Mol Med. 2008;86(6): 691-5
- (2008) RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection. Clin Res Cardiol. 2008;97(7): 418-31
- (2008) Efficacy, safety and tolerability of valsartan 80 mg compared to irbesartan 150 mg in hypertensive patients on long-term hemodialysis (VALID study). Clin Nephrol. 2008;Volume 69(June): 425-432
- (2008) Glutathione S-transferase variants and hypertension. J Hypertens. 2008;26(7): 1343-1352
- (2008) Analysis of retinal arteriolar structure in never-treated patients with essential hypertension. J Hypertens. 2008;26(7): 1427-34
- (2008) The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure - a prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens. 2008;26(7): 1487-1496
- (2008) [Combination therapy: used too little and too late?] MMW Fortschr Med. 2008;150(24): 27-8, 30
- (2008) Impact of the endothelial nitric oxide synthase gene G894T polymorphism on renal endothelial function in patients with type 2 diabetes. Pharmacogenet Genomics. 2008;18(8): 699-707
- (2008) [Effects of Long-Term Antihypertensive Therapy with Losartan on Blood Pressure and Cognitive Function in Patients with Essential Hypertension and Other Cerebrovascular Risk Factors (AWARE Observational Study).] Med Klin (Munich). 2008;103(7): 491-9
- (2008) Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: The VALUE trial. Blood Press. 2008;17(3): 170-7
- (2008) Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372(9638): 547-53
- (2008) Blood pressure control in patients with comorbidities. J Clin Hypertens (Greenwich). 2008;10(8): 624-31
- (2008) A novel-1364A/C aquaporin 5 gene promoter polymorphism influences the responses to salt loading of the renin-angiotensin-aldosterone system and of blood pressure in young healthy men. Basic Res Cardiol. 2008;103(6): 598-610
- (2008) Effects of telmisartan and ramipril on adiponectin and blood pressure in patients with type 2 diabetes. Am J Hypertens. 2008;21(12): 1330-6
- (2008) Urinary proteomic biomarkers in coronary artery disease. Mol Cell Proteomics. 2008;7(2): 290-8
- (2008) Hypertensive retinopathy: a window to vascular remodeling in arterial hypertension. Hypertension. 2008;51(1): 43-4
- (2008) Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2008;23(2): 573-9
- (2008) Role of asymmetric dimethylarginine for angiotensin II-induced target organ damage in mice. Am J Physiol Heart Circ Physiol. 2008;294(2): H1058-66
- (2008) Analysis of NO-synthase expression and clinical risk factors in human diabetic nephropathy. Nephrol Dial Transplant. 2008;23(4): 1346-54
- (2008) Rosuvastatin improves basal nitric oxide activity of the renal vasculature in patients with hypercholesterolemia. Atherosclerosis. 2008;196(2): 704-11
- (2007) Effects of nitric oxide synthase inhibition and l-arginine on renal haemodynamics in young patients at high cardiovascular risk. Atherosclerosis. 2007;192(1): 155-160
- (2007) Aliskiren, an orally effective Renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens. 2007;20(1): 11-20
- (2007) MDR1 genotype-dependent regulation of the aldosterone system in humans. Pharmacogenet Genomics. 2007;17(2): 137-44
- (2007) Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care. 2007;30(6): 1351-6
- (2007) Contribution of endothelial nitric oxide to blood pressure in humans. Hypertension. 2007;49(5): e29; author reply e30
- (2007) Renin-angiotensin system and cardiovascular risk. Lancet. 2007;369(9568): 1208-19
- (2007) Low-grade albuminuria and cardiovascular risk : What is the evidence? Clin Res Cardiol. 2007;96(5): 247-257
- (2007) 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25(6): 1105-87
- (2007) The potential role of prorenin in diabetic nephropathy. J Hypertens. 2007;25(7): 1323-6
- (2007) Involvement of endothelial mechanisms in L-arginine-induced alterations of renal haemodynamics in humans. J Hypertens. 2007;25(7): 1515-6
- (2007) Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. Int J Clin Pract. 2007;61(9): 1461-8
- (2007) Sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: substudy of the ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telm Am Heart J. 2007;154(1): 94-101
- (2007) Cardiovascular risk reduction by reversing endothelial dysfunction: ARBs, ACE inhibitors, or both? Expectations from the ONTARGET Trial Programme. Vasc Health Risk Manag. 2007;3(1): 1-9
- (2007) Effect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA study. Kidney Blood Press Res. 2007;30(5): 314-22
- (2007) High sodium intake modulates left ventricular mass in patients with G expression of +1675 G/A angiotensin II receptor type 2 gene. J Hypertens. 2007;25(8): 1627-32
- (2007) Untitled Herz. 2007;32(3): A15-A15
- (2007) 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28(12): 1462-536
- (2007) [Practice guidelines 2007 for the treatment of arterial hypertension] G Ital Cardiol (Rome). 2007;8(7): 389-479
- (2007) Increased wall:lumen ratio of retinal arterioles in male patients with a history of a cerebrovascular event. Hypertension. 2007;50(4): 623-9
- (2007) [High blood pressure and changes in the ocular fundus] MMW Fortschr Med. 2007;149(27-28): 39-41
- (2007) 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens. 2007;25(9): 1751-1762
- (2007) Left-ventricular structure and function are influenced by angiotensinogen gene polymorphism (-20 a/c) in young male patients. Am J Hypertens. 2007;20(9): 974-80
- (2007) Fourier analysis of the envelope of the ophthalmic artery blood flow velocity: age- and blood pressure related impact. Hypertension. 2007;50(5): 964-9
- (2007) 2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Press. 2007;16(3): 135-232
- (2007) [Albuminuria: an indicator of cardiovascular risk.] Med Klin (Munich). 2007;102(10): 833-43
- (2007) [ESH/ESC 2007 Guidelines for the management of arterial hypertension] Rev Esp Cardiol. 2007;60(9): 968.e1-94
- (2007) [Care of hypertensive patients seen by cardiologists: results of the Snapshot Hypertension Registry] Dtsch Med Wochenschr. 2007;132(46): 2430-5
- (2007) [Guidelines 2007 of the European Societies of Hypertension and of Cardiology: what has changed?] Dtsch Med Wochenschr. 2007;132(46): 2463-6
- (2007) Participation preferences of patients with acute and chronic conditions. Health Expect. 2007;10(4): 358-63
- (2007) Ambulatory blood pressure in hypertensive patients with left ventricular hypertrophy: efficacy of first-line combination perindopril/indapamide therapy. Vasc Health Risk Manag. 2007;3(4): 371-80
- (2007) Renin-angiotensin system and cardiovascular risk - Reply Lancet. 2007;370(9581): 24-25
- (2007) Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes (vol 30, pg 1351, 2007) Diabetes Care. 2007;30(9): 2421-2421
- (2007) Score-based immunoglobulin G therapy of patients with sepsis: the SBITS study. Crit Care Med. 2007;35(12): 2693-2701
- (2007) New developments with nephroprotection Herz. 2007;32(5): A11-A11
- (2007) Renin inhibitors: optimal strategy for renal protection. Curr Hypertens Rep. 2007;9(5): 415-21
- (2006) Endothelial dysfunction: how can one intervene at the beginning of the cardiovascular continuum? J Hypertens. 2006;24 Suppl.(): S31-S35
- (2006) Endothelial dysfunction: how can one intervene at the beginning of the cardiovascular continuum? J Hypertens Suppl. 2006;24(2): S31-5
- (2006) EFFECT OF NOS INHIBITION ON RETINAL ARTERIAL AND CAPILLARY CIRCULATION IN EARLY ARTERIAL HYPERTENSION. Retina. 2006;26(4): 437-444
- (2006) Subtotal nephrectomy impairs ischemia-induced angiogenesis and hindlimb re-perfusion in rats. Kidney Int. 2006;69(11): 2013-21
- (2006) Influences of norepinephrine transporter function on the distribution of sympathetic activity in humans. Hypertension. 2006;48(1): 120-6
- (2006) Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. J Hypertens. 2006;24(7): 1405-1412
- (2006) Impaired basal NO activity in patients with glomerular disease and the influence of oxidative stress. Kidney Int. 2006;70(6): 1177-81
- (2006) Valsartan and retinal endothelial function in elderly hypertensive patients. Blood Press. 2006;15(3): 185-91
- (2006) The Effects of Paracetamol and Parecoxib on Kidney Function in Elderly Patients Undergoing Orthopedic Surgery. Anesth Analg. 2006;103(5): 1170-1176
- (2006) Angiotensin receptor blockers: Cardiovascular protection in the metabolic syndrome. J Renin Angiotensin Aldosterone Syst. 2006;7 Suppl 1(): S12-8
- (2006) [Shared decision-making in hypertension.] Dtsch Med Wochenschr. 2006;131(46): 2592-2596
- (2006) [Established and new parameters of hypertensive target organ damage.] Dtsch Med Wochenschr. 2006;131(46 spezial): H20-H23
- (2006) [Low grade albuminuria, microalbuminuria and proteinuria - accepted cardiovascular risk markers?] Dtsch Med Wochenschr. 2006;131(47): 2665-2671
- (2006) Aliskiren: a clinical profile. J Renin Angiotensin Aldosterone Syst. 2006;7 Suppl 2(): S16-20
- (2006) Rapid nongenomic effects of aldosterone on the renal vasculature in humans. Hypertension. 2006;47(4): 650-5
- (2006) Indapamide SR versus candesartan and amlodipine in hypertension: the X-CELLENT Study. Am J Hypertens. 2006;19(1): 113-21
- (2005) Enhanced levels of platelet P-selectin and circulating cytokines in young patients with mild arterial hypertension. J Hypertens. 2005;23(5): 995-1000
- (2005) [Multi-centre enquiry into the influence of the referral of patients with progressive kidney disease to nephrologists.] Dtsch Med Wochenschr. 2005;130(13): 792-6
- (2005) Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin Pract. 2005;100(1): c8-19
- (2005) Optimizing therapeutic strategies to achieve renal and cardiovascular risk reduction in diabetic patients with angiotensin receptor blockers. J Hypertens. 2005;23(5): 905-11
- (2005) Mechanisms for the Clinical Benefits of Angiotensin II Receptor Blockers. Am J Hypertens. 2005;18(5): 720-30
- (2005) Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. Am Heart J. 2005;149(3): 473
- (2005) Effect of rosuvastatin on outcomes in chronic haemodialysis patients - design and rationale of the AURORA study. Curr Control Trials Cardiovasc Med. 2005;6(1): 9
- (2005) [In Process Citation] Krankenpfl J. 2005;43(1-3): 63
- (2005) Superoxide scavenging effects of N-acetylcysteine and vitamin C in subjects with essential hypertension. Am J Hypertens. 2005;18(8): 1111-7
- (2005) [Observational study of blood pressure control and microalbuminuria in type 2 diabetics on Irbesartan or Irbesartan/HCTZ] MMW Fortschr Med. 2005;147(31-32): 713
- (2005) Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. J Am Soc Nephrol. 2005;16(10): 3038-45
- (2005) CYP3A5 genotype is associated with elevated blood pressure. Pharmacogenet Genomics. 2005;15(10): 737-41
- (2005) [Observational study of blood pressure control and microalbuminuria in type 2 diabetics on irbesartan or irbesartan/HCTZ] MMW Fortschr Med. 2005;147 Suppl(): 97-101
- (2005) Long-Term Efficacy and Tolerability of Lanthanum Carbonate: Results from a 3-Year Study. Nephron Clin Pract. 2005;102(2): c61-c71
- (2005) Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study. J Hypertens. 2005;23(11): 2063-70
- (2005) Cardiotrophin: its importance as a pathogenetic factor and as a measure of left ventricular hypertrophy. J Hypertens. 2005;23(12): 2151-3
- (2005) The role of non-haemodynamic factors of the genesis of LVH. Nephrol Dial Transplant. 2005;20(12): 2610-2612
- (2005) Effects of erythropoietin on retinal capillary flow in humans J Hypertens. 2005;23 Suppl.(): 59-59
- (2005) Effects of Sympathetic Nerves and Angiotensin II on Renal Sodium and Water Handling in Rats with Common Bile Duct Ligature. Am J Physiol Renal Physiol. 2005;288(6): F1267-75
- (2005) Effects of erythropoietin on retinal capillary flow in normotensive and hypertensive subjects Nephrol Dial Transplant. 2005;20 Suppl.(): V195-V195
- (2005) Effects of telmisartan versus ramipril on endothelium function of the renal vasculature in type 2 diabetes Nephrol Dial Transplant. 2005;20 Suppl.(): V242-V242
- (2005) The progression of autosomal dominant polycystic kidney disease is modified in patients with a promoter polymorphism of the alpha 8 integrin gene Nephrol Dial Transplant. 2005;20 Suppl.(): V245-V245
- (2005) Dose-response effect of angiotensin receptor blocker candesartan on proteinuria: A double blind, randomized study Nephrol Dial Transplant. 2005;20 Suppl.(): V69-V69
- (2005) Changes in plasma renin match the antihypertensive effects of aliskiren in patients with hypertension: Placebo/irbesartan-controlled trial with the orally active renin inhibitor aliskiren Am J Hypertens. 2005;18(5): 234A-234A
- (2005) Effects of irbesartan versus atenolol on vascular stiffness and aortic blood pressure in essential hypertension J Hypertens. 2005;23 Suppl.(): S13-S13
- (2005) Effects of telmisartain versus ramipril on endothelium function of the renal vasculature in type 2 diabetes J Hypertens. 2005;23 Suppl.(): S147-S147
- (2005) Aldosterone release during head up tilt is related to left ventricular diastolic function J Hypertens. 2005;23 Suppl.(): S167-S167
- (2005) Impact of vitamin C as an antioxidative agent on renal hemodynamics in normotensive and hypertensive subjects J Hypertens. 2005;23 Suppl.(): S178-S179
- (2005) Single locus and haploptype analyses of human glutathione-s-transferase type MU (GSTM) gene cluster suggest association of GSTM4 to indices of endothelial function and hypertension status J Hypertens. 2005;23 Suppl.(): S246-S247
- (2005) The secret study - Study on evaluation of candesartan cilexetil after renal transplantation J Hypertens. 2005;23 Suppl.(): S3-S3
- (2005) Antihypertensive therapy - Is a shared decision making approach more effective? J Hypertens. 2005;23 Suppl.(): S318-S318
- (2005) Dose-response effect of angiotensin receptor blocker candesartan on proteinuria: A double blind, randomized study J Hypertens. 2005;23 Suppl.(): S328-S328
- (2005) Does acute volume depletion influence the assessment of left ventricular structure, function and vascular compliance J Hypertens. 2005;23 Suppl.(): S9-S9
- (2005) Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation. 2005;111(8): 1012-8
- (2005) [In Process Citation] MMW Fortschr Med. 2005;147(3): 10
- (2005) Critical value of the electrocardiogram in LVH: From predictive index to therapeutic reassessment - Response Hypertension. 2005;45(2): E6-E7
- (2005) Monitoring of peripheral blood cytotoxic T-cells under fluvastatin treatment in renal transplant recipients. J Biol Regul Homeost Agents. 2005;19(3-4): 159-68
- (2005) Does perindopril/indapamide combination have a blood pressure independent effect on left ventricular mass evolution? The picxel study J Hypertens. 2005;23 Suppl.(): S191-S192
- (2005) Decrease of systolic blood pressure in mild-to-moderate hypertension: Are genetic polymophisms helpful? The X-CELLENT genetics substudy J Hypertens. 2005;23 Suppl.(): S364-S365
- (2005) Picxel: Perindopril/indapamide 24-hour ABPM efficacy in hypertensive patients with left ventricular hypertrophy J Hypertens. 2005;23 Suppl.(): S81-S81
- (2005) CYP3A5 genotype is associated with elevated blood pressure Pharmacogenet Genomics. 2005;61(9): 716-716
- (2004) Is the afferent arteriole the main location of nitric oxide action and synthesis in humans? Reply Nephrol Dial Transplant. 2004;19(11): 2925-2926
- (2004) Re: Heusser et al: Elevation of sympathetic activity by eprosartan in young male subjects - In reply Am J Hypertens. 2004;17(3): 281-283
- (2004) Response: Rapid nongenomic effects of aldosterone on human forearm vasculature Hypertension. 2004;43(5): E30-E30
- (2004) Low-dose Perindopril, indapamide and eccentric, concentric left ventricular hypertrophy in the PICXEL study Eur Heart J. 2004;25 Suppl.(): 208-208
- (2004) Impaired endothelial function of the retinal vasculature in hypertensive patients. Stroke. 2004;35(6): 1289-93
- (2004) The role of nitric oxide in the regulation of glomerular haemodynamics in humans. Nephrol Dial Transplant. 2004;19(6): 1392-7
- (2004) Increased response of renal perfusion to the antioxidant vitamin C in type 2 diabetes. Nephrol Dial Transplant. 2004;19(10): 2513-8
- (2004) Effect of irbesartan versus atenolol on left ventricular mass and voltage: results of the CardioVascular Irbesartan Project. Hypertension. 2004;44(1): 61-6
- (2004) Renal endothelial effects of antihypertensive therapy. Curr Opin Nephrol Hypertens. 2004;13(5): 489-93
- (2004) The effect of statins on angiotensin II-induced hemodynamic changes in young, mildly hypercholesterolemic men. Am J Hypertens. 2004;17(12 Pt 1): 1120-6
- (2004) Intensive training of patients with hypertension is effective in modifying lifestyle risk factors. J Hum Hypertens. 2004;18(2): 127-31
- (2004) Response: Rapid Nongenomic Effects of Aldosterone on Human Forearm Vasculature. Hypertension. 2004;():
- (2004) Response. Expert Opin Pharmacother. 2004;():
- (2004) [A model project on shared decision-making in the treatment of arterial hypertension] MMW Fortschr Med. 2004;146(16): 48-50
- (2004) Effect of erythropoietin on cardiovascular prognosis parameters in hemodialysis patients. Kidney Int. 2004;66(2): 832-40
- (2004) Telmisartan/hydrochlorothiazide combination therapy in the treatment of essential hypertension. Expert Opin Pharmacother. 2004;5(11): 2303-10
- (2004) Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens. 2004;17(2): 103-11
- (2004) Serial echocardiographic assessment of left ventricular mass: how blinded should readers be? J Hypertens. 2004;22(9): 1813-8
- (2004) Aliskiren, a novel orally effective renin inhibitor, provides antihypertensive efficacy and placebo-like tolerability similar to an AT(1)-receptor blocker in hypertensive patients Am J Hypertens. 2004;17(5): 108A-108A
- (2004) The effect of Valsartan on the endothelial function of the retinal capillary bed in elderly hypertensive subjects Am J Hypertens. 2004;17(5): 62A-62A
- (2004) Impaired stimulated no-activity by erythropoetin in hypertensive subjects Am J Hypertens. 2004;17(5): 73A-73A
- (2004) Effects of the angiotensin-1 receptor blocker valsartan compared with amlodipine on renal hemodynamics - Reply Am J Hypertens. 2004;17(7): 639-640
- (2004) Platelet P-selectin and plasma levels of circulating cytokines in young patients with mild essential hypertension Eur Heart J. 2004;25 Suppl.(): 108-109
- (2004) Rapid nongenomic aldosterone effects in the human forearm? Response Hypertension. 2004;43(1): E2-E2
- (2004) Platelet P-selectin and plasma levels of circulating cytokines in young patients with mild arterial hypertension J Am Coll Cardiol. 2004;43 Suppl.(5): 12A-12A
- (2004) The G1675A gene polymorphism of the angiotensin II type 2-receptor gene influences cardiac structural response to antihypertensive therapy J Am Coll Cardiol. 2004;43 Suppl.(5): 511A-511A
- (2004) Determinants of the time course of LVH-regression: The VALUE-trial J Hypertens. 2004;22 Suppl.(): S7-S7
- (2004) The effect of Valsartan on the endothelial function of the retinal capillary bed J Hypertens. 2004;22 Suppl.(): S143-S143
- (2004) Platelet P-selectin and plasma levels of circulating cytokines in young patients with mild essential hypertension J Hypertens. 2004;22 Suppl.(): S178-S178
- (2004) A single nucleotide polymorphism (SNP) in the human glutathione S-transferase mu type 4 gene (Gstm 4) is associated with impaired endothelial function and arterial hypertension J Hypertens. 2004;22 Suppl.(): S212-S212
- (2004) Determinants of the new development of left ventricular hypertrophy on treated hypertensives: The VALUE-trial J Hypertens. 2004;22 Suppl.(): S277-S277
- (2004) Cardiac structural adaptation of the left and right ventricle in early stages of essential hypertension J Hypertens. 2004;22 Suppl.(): S277-S277
- (2004) Rapid nongenomic effects of aldosterone in essential hypertension J Hypertens. 2004;22 Suppl.(): S300-S300
- (2004) Impaired stimulated NO-activity by darbepoietin in hypertensive subjects J Hypertens. 2004;22 Suppl.(): S55-S55
- (2004) Effects of ultra high dose candesartan (64mg) on proteinuria: Interim results of a double blind, randomized study J Hypertens. 2004;22 Suppl.(): S79-S80
- (2003) Nitric oxide bioavailability in the retinal vasculature of hypertensive patients Circulation. 2003;108 Suppl.(17): 347-348
- (2003) Determinants for the, treatment in hypertensive patients with autosomal dominant polycystic kidney disease (ADPKD): Choice of drug versus blood pressure (BP) control. J Am Soc Nephrol. 2003;14 Suppl.(): 109A-109A
- (2003) Rapid nongenomic aldosterone effects on the renal perfusion J Am Soc Nephrol. 2003;14 Suppl.(): 146A-146A
- (2003) Rapid nongenomic aldosterone effects - A pathophysiological factor in primary hypertension? J Am Soc Nephrol. 2003;14 Suppl.(): 514A-514A
- (2003) Impaired stimulated NO-Activity by erythropoietin in hypertensive subjects. J Am Soc Nephrol. 2003;14 Suppl.(): 515A-515A
- (2003) Effects of ultra high dose of candesartan (64 mg) on proteinuria: Interim results of a double-blind, randomized, Multicenter study. J Am Soc Nephrol. 2003;14 Suppl.(): 528A-528A
- (2003) Evidence for increased oxidative stress in the renal vasculature of patients with type 2 diabetes. J Am Soc Nephrol. 2003;14 Suppl.(): 608A-608A
- (2003) The importance of nitric oxide (NO) for the regulation of glomerular hemodynamics in humans. J Am Soc Nephrol. 2003;14 Suppl.(): 615A-615A
- (2003) Results on left ventricular structure in the Cardivascular Irbesartan Projekt (CVIP): An 18 month comparison between irbesartan and atenolol. J Am Soc Nephrol. 2003;14 Suppl.(): 673A-673A
- (2003) Successful treatment of peritonitis in a patient using the Vasca Life Site port for peritoneal dialysis. J Am Soc Nephrol. 2003;14 Suppl.(): 863A-863A
- (2003) Hyperemia following ischemia is mediated by nitric oxide. J Am Soc Nephrol. 2003;14 Suppl.(): 872A-872A
- (2003) Nitric oxide activity in the renal vasculature of patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2003;14 Suppl.(): 875A-875A
- (2003) Aldosterone-induced cardiac damage: focus on blood pressure independent effects. Am J Hypertens. 2003;16(1): 80-6
- (2003) Effect of AT1 receptor blockade on endothelial function in essential hypertension. Am J Hypertens. 2003;16(2): 123-8
- (2003) Elevation of sympathetic activity by eprosartan in young male subjects. Am J Hypertens. 2003;16(8): 658-64
- (2003) Direct comparison of the effects of valsartan and amlodipine on renal hemodynamics in human essential hypertension. Am J Hypertens. 2003;16(12): 1030-5
- (2003) [Endothelial function of the human renal vasculature] Dtsch Med Wochenschr. 2003;128(3): 92-6
- (2003) [Control of systolic blood pressure in the VALUE trial after 12 months] Dtsch Med Wochenschr. 2003;128(10): 485-6
- (2003) Functional relevance of aldosterone for the determination of left ventricular mass. Am J Cardiol. 2003;91(3): 297-301
- (2003) Effect of elevated triglyceride levels on endothelium-dependent vasodilation in patients with hypercholesterolemia. Am J Cardiol. 2003;91(4): 482-4
- (2003) Effects of angiotensin II receptor antagonism on the renal hemodynamic response to cardiovascular stress. Kidney Int. 2003;63(2): 617-23
- (2003) The C242T p22phox polymorphism and endothelium-dependent vasodilation in subjects with hypercholesterolaemia. Clin Sci (Lond). 2003;105(1): 97-103
- (2003) Potential mechanisms of impaired endothelial function in arterial hypertension and hypercholesterolemia. Curr Hypertens Rep. 2003;5(3): 199-207
- (2003) L-arginine-induced vasodilation of the renal vasculature is not altered in hypertensive patients with type 2 diabetes. Diabetes Care. 2003;26(6): 1836-40
- (2003) Rapid nongenomic effects of aldosterone on human forearm vasculature. Hypertension. 2003;42(2): 156-60
- (2003) Response. Hypertension. 2003;():
- (2003) A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003;115(1): 41-6
- (2003) Vitamin C augments the renal response to L-arginine in smokers. Nephrol Dial Transplant. 2003;18(8): 1512-7
- (2003) AT1 antagonism by eprosartan lowers heart rate variability and baroreflex gain. Auton Neurosci. 2003;107(1): 45-51
- (2003) Evidence for increased oxidative stress in the renal vasculature of patients with type 2 diabetes J Hypertens. 2003;21 Suppl.(): S105-S105
- (2003) The angiotensinogen genotype affects hypertension in mice and predicts the hypotensive response to AT1 receptor antagonism J Hypertens. 2003;21 Suppl.(): S121-S121
- (2003) Proof of rapid vascular aldosterone effects J Hypertens. 2003;21 Suppl.(): S149-S150
- (2003) Disparate effects of vitamin C and N-acetylcysteine on vascular dysfunction in subjects with essential hypertension J Hypertens. 2003;21 Suppl.(): S155-S155
- (2003) Reduction of left ventricular mass in essential hypertension: Final results by meta-analysis including all randomized double-blind studies until September 2002 J Hypertens. 2003;21 Suppl.(): S176-S176
- (2003) Interaction of nitric oxide and rapid non-genomic effects of aldosterone on the renal perfusion J Hypertens. 2003;21 Suppl.(): S287-S287
- (2003) Results on left ventricular structure in the Cardiovascular Irbesartan Project (CVIP): An 18 months comparison between irbesartan and atenolol J Hypertens. 2003;21 Suppl.(): S70-S71
- (2003) Vitamin C increases renal plasma flow in patients with type 2 diabetes J Hypertens. 2003;21 Suppl.(): S86-S86
- (2003) [New recommendations of the German Hypertension League for the drug treatment of hypertension] Dtsch Med Wochenschr. 2003;128(47): 2468-9
- (2003) Contribution of nitric oxide (NO) to retinal perfusion is reduced in hypertensive patients but can be restored by treatment with candesartan cilexitil J Hypertens. 2003;21 Suppl.(): S169-S169
- (2002) Efficacy of very low dose perindopril 2 mg/indapamide 0.625 mg combination on left ventricular hypertrophy in hypertensive patients: the P.I.C.X.E.L. study rationale and design. J Hum Hypertens. 2002;16(9): 653-9
- (2002) Are the benefits of antihypertensive therapy only due to blood pressure reduction? J Hypertens. 2002;20(10): 2095-6; author reply 2096
- (2002) Altered aldosterone response to salt intake and angiotensin II infusion in young normotensive men with parental history of arterial hypertension. J Hypertens. 2002;20(1): 117-24
- (2002) Association studies in cardiovascular medicine. J Hypertens. 2002;20(2): 173-6
- (2002) Impact of NO-synthase inhibition on renal hemodynamics in normotensive and hypertensive subjects. J Hypertens. 2002;20(3): 525-30
- (2002) Neutral endopeptidase inhibition: the potential of a new therapeutic approach in cardiovascular disease evolves. J Hypertens. 2002;20(4): 599-603
- (2002) AT1-receptor blockade improves augmentation index: a double-blind, randomized, controlled study. J Hypertens. 2002;20(12): 2423-8
- (2002) [Are COX-2 inhibitors a risk factor for cardiovascular disease?] Dtsch Med Wochenschr. 2002;127(4): 156-9
- (2002) Assessment of endothelial function of the renal vasculature in human subjects. Am J Hypertens. 2002;15(1 Pt 1): 3-9
- (2002) Angiotensin converting enzyme inhibition and angiotensin II AT1-receptor blockade reduce the levels of asymmetrical N(G), N(G)-dimethylarginine in human essential hypertension. Am J Hypertens. 2002;15(7 Pt 1): 590-3
- (2002) Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension. Kidney Int. 2002;61(4): 1462-8
- (2002) [Microalbuminuria. Test for this risk factor!] MMW Fortschr Med. 2002;144(15): 47-8
- (2002) [Left ventricular hypertrophy. Recent aspects of diagnosis and therapy] MMW Fortschr Med. 2002;144(42): 45-6
- (2002) Hypercholesterolaemia and treatment with statins do not alter L-arginine-induced changes of renal haemodynamics. Nephrol Dial Transplant. 2002;17(10): 1758-65
- (2002) Are all antihypertensive drug classes equal in reducing left ventricular hypertrophy? Curr Cardiol Rep. 2002;4(6): 474-8
- (2002) Different effects of amlodipine and valsartan on renal haemodynamics in essential hypertension Eur Heart J. 2002;23 Suppl.(): 496-496
- (2002) Vitamin C augments the renal response to L-arginine in smokers J Hypertens. 2002;20 Suppl.(): S104-S104
- (2002) Analysis of endothelial function in the human renal vasculature J Hypertens. 2002;20 Suppl.(): S109-S109
- (2002) Effect of cholesterol lowering agents on angiotensin II-induced blood pressure increase J Hypertens. 2002;20 Suppl.(): S143-S143
- (2002) Statins rapidly improve endothelial function in mildly hypertensive and hypercholesterolemic patients J Hypertens. 2002;20 Suppl.(): S144-S144
- (2002) Effect of the ACE genotype on angiotensin II and renin levels in plasma and kidney tissue J Hypertens. 2002;20 Suppl.(): S16-S16
- (2002) The ACE genotype determines the formation of angiotensin II in resistance vessels J Hypertens. 2002;20 Suppl.(): S16-S16
- (2002) Effect of the angiotensinogen genotype on experimental hypertension in mice J Hypertens. 2002;20 Suppl.(): S17-S17
- (2002) Effects of angiotensin II receptor antagonism on renal hemodynamics J Hypertens. 2002;20 Suppl.(): S221-S221
- (2002) Is basal nitric oxide (NO) bioavailability similarly impaired in the forearm and the renal vasculature? J Hypertens. 2002;20 Suppl.(): S393-S393
- (2002) Divergent effects of amlodipine and valsartan on renal hemodynamics in essential hypertension J Hypertens. 2002;20 Suppl.(): S50-S50
- (2002) ACE-inhibitors, AT(1) receptor antagonists and augmentation index: Is combination therapy superior to monotherapy? J Hypertens. 2002;20 Suppl.(): S75-S75
- (2001) Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia. Circulation. 2001;104(20): 2395-400
- (2001) Effect of the angiotensin II type 2-receptor gene (+1675 G/A) on left ventricular structure in humans. J Am Coll Cardiol. 2001;37(1): 175-82
- (2001) Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin within two weeks. J Am Coll Cardiol. 2001;37(5): 1351-8
- (2001) Aldosterone synthase (CYP11B2) -344 C/T polymorphism is associated with left ventricular structure in human arterial hypertension. J Am Coll Cardiol. 2001;37(3): 878-84
- (2001) Effects of continuous haemofiltration vs intermittent haemodialysis on systemic haemodynamics and splanchnic regional perfusion in septic shock patients: a prospective, randomized clinical trial. Nephrol Dial Transplant. 2001;16(2): 320-7
- (2001) Efficacy and drug interactions of the new HMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treated renal transplant recipients. Nephrol Dial Transplant. 2001;16(1): 141-6
- (2001) G-protein beta(3) subunit gene (GNB3) 825T allele is associated with enhanced renal perfusion in early hypertension. Hypertension. 2001;37(3): 882-6
- (2001) Impaired sodium excretion during mental stress in mild essential hypertension. Hypertension. 2001;37(3): 923-7
- (2001) Renin uptake by the endothelium mediates vascular angiotensin formation. Hypertension. 2001;38(2): 243-8
- (2001) Angiotensinogen gene core promoter variants and non-modulating hypertension. Hypertension. 2001;38(6): 1250-4
- (2001) Salt and hypertension: going to the heart of the matter. Arch Intern Med. 2001;161(4): 505-6
- (2001) The kidney in congestive heart failure: renal adverse event rate of treatment. J Cardiovasc Pharmacol. 2001;38(1): 99-107
- (2001) Outcome survey in unselected hypertensive patients with type 2 diabetes mellitus: effects of ACE inhibition. Am J Hypertens. 2001;14(7 Pt 1): 672-8
- (2001) [Systolic or diastolic blood pressure. Which value is more important?] MMW Fortschr Med. 2001;143(28-29): 37-8
- (2000) Impaired endothelial function in arterial hypertension and hypercholesterolemia: potential mechanisms and differences. J Hypertens. 2000;18(4): 363-74
- (2000) Relationship of renal histological damage to glomerular hypertension in patients with immunoglobulin A nephropathy. J Hypertens. 2000;18(9): 1341-3
- (2000) Lack of association between polymorphisms of angiotensin II receptor genes and response to short-term angiotensin II infusion. J Hypertens. 2000;18(11): 1573-8
- (2000) Functional gene testing of the Glu298Asp polymorphism of the endothelial NO synthase. J Hypertens. 2000;18(12): 1767-73
- (2000) Plasma soluble adhesion molecules and endothelium-dependent vasodilation in early human atherosclerosis. Clin Sci (Lond). 2000;98(5): 521-9
- (2000) Is l-arginine infusion an adequate tool to assess endothelium-dependent vasodilation of the human renal vasculature? Clin Sci (Lond). 2000;99(4): 293-302
- (2000) Impact of aldosterone on left ventricular structure and function in young normotensive and mildly hypertensive subjects. Am J Cardiol. 2000;85(10): 1199-206
- (2000) Plasma endothelin is increased in early essential hypertension. Am J Hypertens. 2000;13(6 Pt 1): 579-85
- (2000) Enhanced antinatriuresis in response to angiotensin II in essential hypertension. Am J Hypertens. 2000;13(9): 986-93
- (2000) Regression of left ventricular hypertrophy by AT1 receptor blockade in renal transplant recipients. Am J Hypertens. 2000;13(12): 1295-300
- (2000) Effects of oral contraceptives on vascular endothelium in premenopausal women. Am J Obstet Gynecol. 2000;183(1): 28-33
- (2000) Vascular reactivity in patients with preeclampsia and HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome. Am J Obstet Gynecol. 2000;183(6): 1489-94
- (2000) [Nürnberg Prevention Survey. "Prevention yes--but only when no effort is required"] MMW Fortschr Med. 2000;142(33-34): 46
- (2000) Prospective analysis of the value of 24-hour ambulatory blood pressure on renal function after kidney transplantation. Transplantation. 2000;70(5): 819-27
- (2000) Diuretic therapy and the risk for renal cell carcinoma. J Nephrol. 2000;13(5): 343-6
- (2000) Hypertension and the heart. J Hum Hypertens. 2000;14(10-11): 597-604
- (2000) [Antihypertensive therapy in the year 2000: status] Dtsch Med Wochenschr. 2000;125(46): 1384
- (2000) [Results of an intensive training program for hypertension at the Institute for Preventive Medicine] Dtsch Med Wochenschr. 2000;125(46): 1385-9
- (2000) Determinants of left ventricular structure after kidney transplantation. Transplant Proc. 2000;32(8): 2801-6
- (2000) Mildly elevated homocysteine concentrations impair endothelium dependent vasodilation in hypercholesterolemic patients. Atherosclerosis. 2000;153(2): 383-9
- (1999) [Diuretic therapy and the risk of renal-cell carcinoma] Dtsch Med Wochenschr. 1999;124(14): 410-1
- (1999) Angiotensin II stimulates left ventricular hypertrophy in hypertensive patients independently of blood pressure. Am J Hypertens. 1999;12(4 Pt 1): 418-22
- (1999) Renal cell carcinoma and diuretics--should one restrict the use of diuretics? Nephrol Dial Transplant. 1999;14(7): 1621-3
- (1999) Not all left ventricular hypertrophy is created equal. Nephrol Dial Transplant. 1999;14(12): 2803-5
- (1999) Diuretics for hypertension. JAMA. 1999;282(6): 523; author reply 525
- (1999) Hyper-responsiveness to angiotensin II is related to cardiac structural adaptation in hypertensive subjects. J Hypertens. 1999;17(6): 825-33
- (1999) 825T allele of the G-protein beta3 subunit gene (GNB3) is associated with impaired left ventricular diastolic filling in essential hypertension. J Hypertens. 1999;17(10): 1457-62
- (1999) Low-density lipoprotein-cholesterol determines vascular responsiveness to angiotensin II in normocholesterolaemic humans. J Hypertens. 1999;17(12 Pt 2): 1933-9
- (1999) 1166 A/C polymorphism of the angiotensin II type 1 receptor gene and the response to short-term infusion of angiotensin II. Circulation. 1999;100(13): 1394-9
- (1999) Relation between the renin-angiotensin-aldosterone system and left ventricular structure and function in young normotensive and mildly hypertensive subjects. Am Heart J. 1999;138(5 Pt 1): 810-7
- (1999) Soluble thrombomodulin and endothelial dysfunction in early atherosclerosis. Lancet. 1999;354(9190): 1647
- (1998) Angiotensinases restrict locally generated angiotensin II to the blood vessel wall. Hypertension. 1998;31(1 Pt 2): 368-72
- (1998) Does lipoprotein(a) impair endothelial function? J Am Coll Cardiol. 1998;31(2): 359-65
- (1998) Inadequate suppression of angiotensin II modulates left ventricular structure in humans. Clin Nephrol. 1998;49(3): 153-9
- (1998) Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). Nephrol Dial Transplant. 1998;13(3): 564-9
- (1998) [Association between medication with calcium antagonists and increased cardiovascular mortality is not established] Fortschr Med. 1998;116(8): 51-2
- (1998) Impact of dietary sodium intake on left ventricular diastolic filling in early essential hypertension. Eur Heart J. 1998;19(6): 951-8
- (1998) Effects of naloxone on hemodynamic and sympathetic nerve responses to pain in normotensive vs. borderline hypertensive men. J Auton Nerv Syst. 1998;69(1): 49-55
- (1998) Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study. Circulation. 1998;98(3): 211-6
- (1998) Evidence against elevated sympathetic vasoconstrictor activity in borderline hypertension. J Am Soc Nephrol. 1998;9(9): 1581-7
- (1998) Vasodilatory capacity of forearm resistance vessels is augmented in hypercholesterolemic patients after treatment with fluvastatin. Angiology. 1998;49(9): 743-8
- (1998) Left ventricular hypertrophy and its regression: pathophysiology and therapeutic approach: focus on treatment by antihypertensive agents. Am J Hypertens. 1998;11(11 Pt 1): 1394-404
- (1998) Nephroprotection by antihypertensive therapy. Basic Res Cardiol. 1998;93 Suppl 2(): 109-19
- (1998) Endogenous angiotensin II and the reflex response to stimulation of cardiopulmonary serotonin 5HT3 receptors. Br J Pharmacol. 1998;125(8): 1761-7
- (1997) Endogenous erythropoietin correlates with blood pressure in essential hypertension. Am J Kidney Dis. 1997;29(3): 376-82
- (1997) Is endothelial function of the radial artery altered in human essential hypertension? Am J Hypertens. 1997;10(3): 323-31
- (1997) Renal and systemic hemodynamics in black and white hypertensive patients. Am J Hypertens. 1997;10(9 Pt 1): 971-8
- (1997) Impact of alpha- versus beta-blockers on hypertensive target organ damage: results of a double-blind, randomized, controlled clinical trial. Am J Hypertens. 1997;10(9 Pt 1): 985-91
- (1997) Discontinuation of antihypertensive therapy: prevalence of relapses and predictors of successful withdrawal in a hypertensive community. Cardiology. 1997;88(3): 277-84
- (1997) Dietary salt intake and left ventricular hypertrophy. Nephrol Dial Transplant. 1997;12(2): 245-8
- (1997) Is endogenous erythropoietin a pathogenetic factor in the development of essential hypertension? Nephrol Dial Transplant. 1997;12(6): 1155-60
- (1997) Blood pressure independent effects of nitrendipine on cardiac structure in patients after renal transplantation. Nephrol Dial Transplant. 1997;12(7): 1441-7
- (1997) Glomerular hyperfiltration during sympathetic nervous system activation in early essential hypertension. J Am Soc Nephrol. 1997;8(6): 893-900
- (1997) Comparison of early target organ damage between blacks and whites with mild systemic arterial hypertension. Am J Cardiol. 1997;79(12): 1695-8
- (1997) Salt. A perpetrator of hypertensive target organ disease? Arch Intern Med. 1997;157(21): 2449-52
- (1997) Comparison of therapeutic studies on regression of left ventricular hypertrophy. Adv Exp Med Biol. 1997;432(): 191-8
- (1996) Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA. 1996;275(19): 1507-13
- (1996) Dietary sodium and blood pressure. JAMA. 1996;276(18): 1469; author reply 1469-7
- (1996) Glomerular hyperfiltration in essential hypertension: cause or consequence? Contrib Nephrol. 1996;119(): 91-7
- (1996) Angiotensin II related to sodium excretion modulates left ventricular structure in human essential hypertension. Circulation. 1996;94(6): 1304-9
- (1996) Epicardial bradykinin B2 receptors elicit a sympathoexcitatory reflex in rats. Hypertension. 1996;28(4): 615-21
- (1996) Nerve-mediated antidiuresis and antinatriuresis after air-jet stress is modulated by angiotensin II. Hypertension. 1996;28(5): 825-32
- (1996) Hemodynamic and sympathetic nerve responses to painful stimuli in normotensive and borderline hypertensive subjects. Pain. 1996;66(2-3): 117-24
- (1996) Preeclampsia -- a state of sympathetic overactivity. N Engl J Med. 1996;335(20): 1480-5
- (1996) Treatment and post-treatment effects of alpha- versus beta-receptor blockers on left ventricular structure and function in essential hypertension. Am Heart J. 1996;132(5): 1004-9
- (1996) Effects of angiotensin converting enzyme inhibitor on renal haemodynamics during mental stress. J Hypertens. 1996;14(10): 1201-7
- (1996) Overview of alpha 1-adrenoceptor antagonism and recent advances in hypertensive therapy. Am J Hypertens. 1996;9(11): 139S-149S
- (1996) Subthreshold stimulation of a serotonin 5-HT3 reflex attenuates cardiovascular reflexes. Am J Physiol. 1996;271(6 Pt 2): R1500-6
- (1996) Antihypertensive efficacy and orthostatic tolerance of bunazosin vs nitrendipine: a multicentre double-blind randomized controlled study. J Hum Hypertens. 1996;10(12): 831-6
- (1995) Improved classification of dippers by individualized analysis of ambulatory blood pressure profiles. Am J Hypertens. 1995;8(7): 666-71
- (1995) Gender-specific cardiovascular adaptation due to circadian blood pressure variations in essential hypertension. Am J Hypertens. 1995;8(12 Pt 1): 1160-6
- (1995) Salt intake as a determinant of cardiac hypertrophy. Blood Press Suppl. 1995;2(): 30-4
- (1995) Central blood volume: a determinant of early cardiac adaptation in arterial hypertension? J Am Coll Cardiol. 1995;26(7): 1692-8
- (1995) [The compliance of the large elastic arteries after blood pressure-lowering therapy with a calcium antagonist] Dtsch Med Wochenschr. 1995;120(25-26): 907-11
- (1995) Is endothelial dysfunction reversible? Am J Cardiol. 1995;76(2): 117A-121A
- (1995) Predictors for hypertensive nephropathy: results of a 6-year follow-up study in essential hypertension. J Hypertens. 1995;13(3): 357-65
- (1995) Effects of bromocriptine on cardiovascular regulation in healthy humans. Hypertension. 1995;25(5): 1075-82
- (1995) Normalization of circadian blood pressure profiles after renal transplantation. Transplantation. 1995;59(9): 1270-4
- (1995) How should renal hemodynamic data be indexed in obesity? J Am Soc Nephrol. 1995;5(9): 1709-13
- (1995) Salt and left ventricular hypertrophy: what are the links? J Hum Hypertens. 1995;9(11): 909-16
- (1995) BROMOCRIPTINE LOWERS SYMPATHETIC ACTIVITY PERIPHERALLY BUT NOT CENTRALLY DURING BAROREFLEX PERTURBATION Nieren und Hochdruckkrankheiten. 1995;24(1): 23-25
- (1994) Obesity and hypertension. Curr Opin Nephrol Hypertens. 1994;3(5): 546-9
- (1994) Renal hemodynamic response to stress is influenced by ACE-inhibitors. Clin Nephrol. 1994;42(6): 381-8
- (1994) Nephroprotection by antihypertensive agents. J Cardiovasc Pharmacol. 1994;24 Suppl 2(): S55-64
- (1994) Salt intake, blood pressure, and cardiovascular structure. Cardiovasc Drugs Ther. 1994;8(3): 425-32
- (1994) Efficacy and tolerance of low-dose loop diuretics in hypertension. Cardiology. 1994;84 Suppl 2(): 36-42
- (1994) Comparison of diastolic left ventricular filling and cardiac dysrhythmias in hypertensive patients with and without isolated septal hypertrophy. Am J Cardiol. 1994;74(6): 585-9
- (1994) Accelerated decline in renal perfusion with aging in essential hypertension. Hypertension. 1994;23(3): 351-7
- (1993) [Ventricular arrhythmia and sudden cardiac death: the significance of left ventricular hypertrophy as risk factor] Schweiz Med Wochenschr. 1993;123(4): 99-107
- (1993) [Rational therapy of heart failure] Z Kardiol. 1993;82 Suppl 4(): 7-16
- (1993) Obese hypertensive patients are less effectively treated than lean hypertensives. J Hypertens Suppl. 1993;11(5): S348-9
- (1993) A centripetal shift in intravascular volume triggers the onset of early cardiac adaptation in hypertension. J Hypertens Suppl. 1993;11(5): S94-5
- (1993) Improved prediction of left ventricular mass from ambulatory blood pressure monitoring using average tension-time index. J Hypertens Suppl. 1993;11(5): S98-9
- (1993) Renal hemodynamics and cardiovascular reactivity in the prehypertensive stage. Behav Med. 1993;19(1): 5-12
- (1993) Disparate cardiovascular response to stress tests during isradipine and fosinopril therapy. Am J Cardiol. 1993;72(7): 574-9
- (1993) Obesity as a determinant for response to antihypertensive treatment. BMJ. 1993;307(6903): 537-40
- (1993) Does obesity influence early target organ damage in hypertensive patients? Circulation. 1993;87(5): 1482-8
- (1992) Determinants of ventricular ectopy in hypertensive cardiac hypertrophy. Am Heart J. 1992;123(1): 89-95
- (1992) Hypertensive heart disease--significance of left ventricular hypertrophy. J Cardiovasc Pharmacol. 1992;20 Suppl 6(): S50-5
- (1992) Effect of antihypertensive therapy on the progression of non-diabetic renal disease. Clin Nephrol. 1992;38 Suppl 1(): S74-7
- (1992) Impact of angiotensin converting enzyme inhibition on the haemodynamic profile during laboratory stress tests. J Hum Hypertens. 1992;6(3): 227-32
- (1992) [Pathophysiology of left heart failure with reference to hemodynamic and neurohumoral changes] Acta Med Austriaca. 1992;19(3): 77-82
- (1992) [Decreased blood pressure in sleep and left ventricular hypertrophy in patients with kidney transplants] Z Kardiol. 1992;81 Suppl 2(): 17-9
- (1992) Stress response pattern in obesity and systemic hypertension. Am J Cardiol. 1992;70(11): 1035-9
- (1992) Risks versus benefits of withdrawing antihypertensive therapy. Drug Saf. 1992;7(6): 395-403
- (1992) Is the decrease in arterial pressure the sole factor for reduction of left ventricular hypertrophy? Am J Med. 1992;92(4B): 28S-34S
- (1992) Impact of antihypertensive therapy with isradipine and metoprolol on early markers of hypertensive nephropathy. Am J Hypertens. 1992;5(5 Pt 1): 318-21
- (1991) Elevated serum activity of N-acetyl-beta-glucosaminidase in essential hypertension: diagnostic value and reversal to normal values after antihypertensive therapy. Am J Kidney Dis. 1991;18(6): 638-48
- (1991) Antihypertensive therapy. To stop or not to stop? JAMA. 1991;265(12): 1566-71
- (1991) [Importance of 24-hour blood pressure monitoring in detection of hypertension-induced end organ damage] Z Kardiol. 1991;80 Suppl 1(): 41-7
- (1990) Reversal of left ventricular hypertrophy: a desirable therapeutic goal? J Cardiovasc Pharmacol. 1990;16 Suppl 6(): S16-22
- (1990) When is discontinuation of antihypertensive therapy indicated? Cardiovasc Drugs Ther. 1990;4(6): 1487-94
- (1990) Relation of hemodynamic reaction during stress to left ventricular hypertrophy in essential hypertension. Am J Hypertens. 1990;3(4): 281-7
- (1990) Risk reduction following regression of cardiac hypertrophy. Clin Exp Hypertens A. 1990;12(5): 903-16
- (1990) [Determinants for myocardial hypertrophy in mild essential hypertension. The effect of sodium chloride on left-ventricular hypertrophy] Z Kardiol. 1990;79(8): 557-64
- (1990) [Arterial hypertension, left ventricular hypertrophy and sudden cardiac death] Dtsch Med Wochenschr. 1990;115(44): 1682-7
- (1990) Glomerular hyperfiltration indicates early target organ damage in essential hypertension. JAMA. 1990;264(21): 2775-80
- (1988) Ambulatory blood pressure monitoring: practical considerations. Am Heart J. 1988;116(4): 1146-51
- (1988) Hemodynamic response patterns to mental stress: diagnostic and therapeutic implications. Am Heart J. 1988;116(2 Pt 2): 617-27
- (1987) Biventricular cardiac hypertrophy in essential hypertension. Am Heart J. 1987;114(4 Pt 1): 813-8
- (1986) Heterogeneous pathophysiology of essential hypertension: implications for therapy. Am Heart J. 1986;112(4): 886-93